<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<script src="ga.js" async="" type="text/javascript"></script><script src="avg_ls_dom_001.js" type="text/javascript"></script>
    
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <title>Online Trial Tracker</title>
    
    
    
    
    
    
    
    <script type="text/javascript" src="jquery.js"></script>
    <script type="text/javascript" src="func.js"></script>	
    <script type="text/javascript" src="jquery-1.7.1.min.js"></script>
	<script type="text/javascript" src="jquery-ui-1.8.17.custom.min.js"></script>
    <script type="text/javascript" src="jquery.date_input.js"></script>
    <script type="text/javascript" src="jquery.jdpicker.js"></script>
    <script type="text/javascript" src="init.js"></script>
    <script type="text/javascript" src="chrome.js"></script>
    <script type="text/javascript" src="jquery.hoverintent.minified.js"></script>
    
    <script type="text/javascript" src="jquery.mousewheel.min.js"></script>
	<script type="text/javascript" src="jquery.mcustomscrollbar.js"></script>
    
    <script type="text/javascript">
		var _gaq = _gaq || [];
		_gaq.push(['_setAccount', 'UA-18240582-3']);
		_gaq.push(['_trackPageview']);
		
		(function() {
			var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
			ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
			var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
      	})();
    </script>
    <script type="text/javascript"> 
    //<![CDATA[
    function showValues(value) 
	{	
          if(value == 'inactive') 
		  {	
          	document.getElementById('statuscontainer').innerHTML = 
				 "<input type='checkbox' class='status' value='0' />Withheld<br/>"+
				 "<input type='checkbox' class='status' value='1' />Approved for marketing<br/>" +
				 "<input type='checkbox' class='status' value='2' />Temporarily not available<br/>" + 
				 "<input type='checkbox' class='status' value='3' />No Longer Available<br/>" + 
				 "<input type='checkbox' class='status' value='4' />Withdrawn<br/>" + 
				 "<input type='checkbox' class='status' value='5' />Terminated<br/>" +
				 "<input type='checkbox' class='status' value='6' />Suspended<br/>" +
				 "<input type='checkbox' class='status' value='7' />Completed<br/>";
          } 
		  else if(value == 'active') 
		  {	
			document.getElementById('statuscontainer').innerHTML = 
				'<input type="checkbox" class="status" value="0" />Not yet recruiting<br/>' +
				'<input type="checkbox" class="status" value="1" />Recruiting<br/>' + 
				'<input type="checkbox" class="status" value="2" />Enrolling by invitation<br/>' + 
				'<input type="checkbox" class="status" value="3" />Active, not recruiting<br/>' + 
				'<input type="checkbox" class="status" value="4" />Available<br/>' +
				'<input type="checkbox" class="status" value="5" />No longer recruiting<br/>';
          } 
		  else 
		  { 
			document.getElementById('statuscontainer').innerHTML = 
				'<input type="checkbox" class="status" value="0" />Not yet recruiting<br/>' +
				'<input type="checkbox" class="status" value="1" />Recruiting<br/>' + 
				'<input type="checkbox" class="status" value="2" />Enrolling by invitation<br/>' + 
				'<input type="checkbox" class="status" value="3" />Active, not recruiting<br/>' + 
				'<input type="checkbox" class="status" value="4" />Available<br/>' +
				'<input type="checkbox" class="status" value="5" />No longer recruiting<br/>' +
				'<input type="checkbox" class="status" value="6" />Withheld<br/>'+
				'<input type="checkbox" class="status" value="7" />Approved for marketing<br/>' +
				'<input type="checkbox" class="status" value="8" />Temporarily not available<br/>' + 
				'<input type="checkbox" class="status" value="9" />No Longer Available<br/>' + 
				'<input type="checkbox" class="status" value="10" />Withdrawn<br/>' + 
				'<input type="checkbox" class="status" value="11" />Terminated<br/>' +
				'<input type="checkbox" class="status" value="12" />Suspended<br/>' +
				'<input type="checkbox" class="status" value="13" />Completed<br/>';
          }
      }
    //]]>
	
	$(function() 
	{
		$("#frmOtt").submit(function() 
		{	
			//set phase filters
			var phase = new Array();
			$('input.phase:checked').each(function(index) 
			{	
				phase.push($(this).val());
			});
			$("#phase").val(phase);
			
			//set region filters
			var region = new Array();
			$('input.region:checked').each(function(index) 
			{	
				region.push($(this).val());
			});
			$("#region").val(region);
			
			//set institution type filters
			var institution = new Array();
			$('input.institution:checked').each(function(index) 
			{	
				institution.push($(this).val());
			});
			$("#itype").val(institution);
			
			//set status filters
			var status = new Array();
			$('input.status:checked').each(function(index) 
			{	
				status.push($(this).val());
			});
			$("#status").val(status);
			
			//set product filters
			var product = new Array();
			$('input.product:checked').each(function(index) 
			{	
				product.push($(this).val());
			});
			$("#product").val(product);
			
			
			//$("#change").val($("#amount3").val());
			
		});
		
		//reset functionality
		$("#reset").click(function() 
		{	
			$("#status").val("");
			$('input.status').each(function(index) 
			{	
				 $(this).attr("checked", false);
			});
			
			$("#itype").val("");
			$('input.institution').each(function(index) 
			{	
				 $(this).attr("checked", false);
			});
			
			$("#region").val("");
			$('input.region').each(function(index) 
			{	
				 $(this).attr("checked", false);
			});
			
			$("#phase").val("");
			$('input.phase').each(function(index) 
			{	
				 $(this).attr("checked", false);
			});

			$('#showonlyupdated').attr("checked", false);
			
			$("#amount").val("0 - 0");
			$( "#slider-range").slider( "option", "value", parseInt(0));
			
			return true;
		});
		
		var config = {    
			 over: makeTall, // function = onMouseOver callback (REQUIRED)    
			 timeout: 500, // number = milliseconds delay before onMouseOut    
			 out: makeShort// function = onMouseOut callback (REQUIRED)   
		};
		
		function makeTall(){  $(this).animate({"height":"100%"}, 500);}
		function makeShort(){ $(this).animate({"height":"16px"}, 500);}

		$(".rowcollapse").hoverIntent(config);
	});
	
    </script>
    
    <script type="text/javascript">
	//Count the Number of View of Records
	function INC_ViewCount(larvol_id)
	{
		 $.ajax({
					type: 'GET',
					url:  'viewcount.php',
					data: "op=Inc_ViewCount&larvol_id="+larvol_id,
					success: function (html) {
						$("#ViewCount_"+larvol_id).html(html);
				   }
		});
	    return;
		
	}
	</script>
    
<link rel="stylesheet" type="text/css" href="index_1.css" media="all">
</head>
<body>
<form id="frmOtt" name="frmOtt" method="get" target="_self" action="http://www.larvoltrials.com/intermediary.php"><input name="LI" value="1" type="hidden"><input name="p" value="4108,2082,3514,2976,4163,3191,4365,1580,255,2778,3615,1887,4101,462,3509,4473,3060,1599,2399,205,2183,1159,2034,3256,1442,572,1038,3607,3407,1392,3168,2835" type="hidden"><input name="a" value="4" type="hidden"><input name="hm" value="179" type="hidden"><input name="pr" id="product" value="" type="hidden"><table class="controls" style="table-layout: fixed; display: none;" align="center" border="0" cellspacing="0"><tbody><tr><td colspan="5" style="border: medium none; height: 29px;"></td></tr><tr><th style="width: 113px;">Active</th><th style="width: 210px;">Status</th><th style="width: 180px;">Institution type</th><th style="width: 80px;">Region</th><th style="width: 50px;">Phase</th><th class="right" style="width: 340px;">Filter</th></tr><tr><td class="bottom" style="padding-right: 5px;"><div style="width: 113px;"><input name="list" value="1" id="active_1" checked="checked" onchange="javascript: showValues('active');" type="radio"><label for="active_1">43 Active</label><br><input name="list" value="0" id="active_0" onchange="javascript: showValues('inactive');" type="radio"><label for="active_0">61 Inactive</label><br><input name="list" value="2" id="active_2" onchange="javascript: showValues('all');" type="radio"><label for="active_2">104 All</label><br></div></td><td class="bottom"><div class="checkscroll" id="statuscontainer" style="width: 210px;"><input class="status" value="0" type="checkbox">Not yet recruiting<br><input class="status" value="1" type="checkbox">Recruiting<br><input class="status" value="2" type="checkbox">Enrolling by invitation<br><input class="status" value="3" type="checkbox">Active, not recruiting<br><input class="status" value="4" type="checkbox">Available<br><input class="status" value="5" type="checkbox">No longer recruiting<br></div></td><td class="bottom"><div style="width: 180px;"><input value="0" id="institution_type_0" class="institution" checked="checked" type="checkbox"><label for="institution_type_0">Industry lead sponsor</label><br><input value="1" id="institution_type_1" class="institution" type="checkbox"><label for="institution_type_1">Industry collaborator</label><br><input value="2" id="institution_type_2" class="institution" type="checkbox"><label for="institution_type_2">Coop</label><br><input value="3" id="institution_type_3" class="institution" type="checkbox"><label for="institution_type_3">Other</label><br></div></td><td class="bottom"><div style="width: 80px;"><input value="0" id="region_0" class="region" type="checkbox"><label for="region_0">US</label><br><input value="1" id="region_1" class="region" type="checkbox"><label for="region_1">Canada</label><br><input value="2" id="region_2" class="region" type="checkbox"><label for="region_2">Japan</label><br><input value="3" id="region_3" class="region" type="checkbox"><label for="region_3">Europe</label><br><input value="4" id="region_4" class="region" type="checkbox"><label for="region_4">RoW</label></div></td><td class="bottom"><div style="width: 50px;"><input value="na" id="phase_na" class="phase" type="checkbox"><label for="phase_na">N/A</label><br><input value="0" id="phase_0" class="phase" type="checkbox"><label for="phase_0">0</label><br><input value="1" id="phase_1" class="phase" type="checkbox"><label for="phase_1">1</label><br><input value="2" id="phase_2" class="phase" type="checkbox"><label for="phase_2">2</label><br><input value="3" id="phase_3" class="phase" type="checkbox"><label for="phase_3">3</label><br><input value="4" id="phase_4" class="phase" type="checkbox"><label for="phase_4">4</label></div></td><td class="right" style="border-bottom: 0px none;"><div class="demo" style="width: 340px;"><p><label for="startrange" style="float: left;">Highlight changes:</label><div class="jdpicker_w"><input id="startrange" name="sr" value="now" class="jdpicker" type="text"><div class="date_selector"><div class="nav"><div class="error_msg"></div><p class="month_nav"><span class="button prev" title="[Page-Up]">«</span> <span class="month_name">October</span> <span class="button next" title="[Page-Down]">»</span></p><p class="year_nav"><span class="button prev" title="[Ctrl+Page-Up]">«</span> <span class="year_name" id="year_name">2012</span> <span class="button next" title="[Ctrl+Page-Down]">»</span></p></div><table><thead><tr><th>M</th><th>T</th><th>W</th><th>T</th><th>F</th><th>S</th><th>S</th></tr></thead><tbody><tr><td class="selectable_day" date="2012-10-01">1</td><td class="selectable_day" date="2012-10-02">2</td><td class="selectable_day" date="2012-10-03">3</td><td class="selectable_day" date="2012-10-04">4</td><td class="selectable_day" date="2012-10-05">5</td><td class="selectable_day" date="2012-10-06">6</td><td class="selectable_day" date="2012-10-07">7</td></tr><tr><td class="selectable_day" date="2012-10-08">8</td><td class="selectable_day" date="2012-10-09">9</td><td class="selectable_day" date="2012-10-10">10</td><td class="selectable_day" date="2012-10-11">11</td><td class="selectable_day" date="2012-10-12">12</td><td class="selectable_day" date="2012-10-13">13</td><td class="selectable_day" date="2012-10-14">14</td></tr><tr><td class="selectable_day today selected" date="2012-10-15">15</td><td class="selectable_day" date="2012-10-16">16</td><td class="selectable_day" date="2012-10-17">17</td><td class="selectable_day" date="2012-10-18">18</td><td class="selectable_day" date="2012-10-19">19</td><td class="selectable_day" date="2012-10-20">20</td><td class="selectable_day" date="2012-10-21">21</td></tr><tr><td class="selectable_day" date="2012-10-22">22</td><td class="selectable_day" date="2012-10-23">23</td><td class="selectable_day" date="2012-10-24">24</td><td class="selectable_day" date="2012-10-25">25</td><td class="selectable_day" date="2012-10-26">26</td><td class="selectable_day" date="2012-10-27">27</td><td class="selectable_day" date="2012-10-28">28</td></tr><tr><td class="selectable_day" date="2012-10-29">29</td><td class="selectable_day" date="2012-10-30">30</td><td class="selectable_day" date="2012-10-31">31</td><td class="unselected_month" date="2012-11-01">1</td><td class="unselected_month" date="2012-11-02">2</td><td class="unselected_month" date="2012-11-03">3</td><td class="unselected_month" date="2012-11-04">4</td></tr></tbody></table></div><span class="date_clearer">&nbsp;</span></div><label style="color: rgb(246, 147, 31); float: left;">-</label><div class="jdpicker_w"><input id="endrange" name="er" value="1 month" style="width: auto; margin-left: 15px;" class="jdpicker" type="text"><div class="date_selector"><div class="nav"><div class="error_msg"></div><p class="month_nav"><span class="button prev" title="[Page-Up]">«</span> <span class="month_name">October</span> <span class="button next" title="[Page-Down]">»</span></p><p class="year_nav"><span class="button prev" title="[Ctrl+Page-Up]">«</span> <span class="year_name" id="year_name">2012</span> <span class="button next" title="[Ctrl+Page-Down]">»</span></p></div><table><thead><tr><th>M</th><th>T</th><th>W</th><th>T</th><th>F</th><th>S</th><th>S</th></tr></thead><tbody><tr><td class="selectable_day" date="2012-10-01">1</td><td class="selectable_day" date="2012-10-02">2</td><td class="selectable_day" date="2012-10-03">3</td><td class="selectable_day" date="2012-10-04">4</td><td class="selectable_day" date="2012-10-05">5</td><td class="selectable_day" date="2012-10-06">6</td><td class="selectable_day" date="2012-10-07">7</td></tr><tr><td class="selectable_day" date="2012-10-08">8</td><td class="selectable_day" date="2012-10-09">9</td><td class="selectable_day" date="2012-10-10">10</td><td class="selectable_day" date="2012-10-11">11</td><td class="selectable_day" date="2012-10-12">12</td><td class="selectable_day" date="2012-10-13">13</td><td class="selectable_day" date="2012-10-14">14</td></tr><tr><td class="selectable_day today selected" date="2012-10-15">15</td><td class="selectable_day" date="2012-10-16">16</td><td class="selectable_day" date="2012-10-17">17</td><td class="selectable_day" date="2012-10-18">18</td><td class="selectable_day" date="2012-10-19">19</td><td class="selectable_day" date="2012-10-20">20</td><td class="selectable_day" date="2012-10-21">21</td></tr><tr><td class="selectable_day" date="2012-10-22">22</td><td class="selectable_day" date="2012-10-23">23</td><td class="selectable_day" date="2012-10-24">24</td><td class="selectable_day" date="2012-10-25">25</td><td class="selectable_day" date="2012-10-26">26</td><td class="selectable_day" date="2012-10-27">27</td><td class="selectable_day" date="2012-10-28">28</td></tr><tr><td class="selectable_day" date="2012-10-29">29</td><td class="selectable_day" date="2012-10-30">30</td><td class="selectable_day" date="2012-10-31">31</td><td class="unselected_month" date="2012-11-01">1</td><td class="unselected_month" date="2012-11-02">2</td><td class="unselected_month" date="2012-11-03">3</td><td class="unselected_month" date="2012-11-04">4</td></tr></tbody></table></div><span class="date_clearer">&nbsp;</span></div><br></p><div class="ui-slider ui-slider-horizontal ui-widget ui-widget-content ui-corner-all" id="slider-range-min" align="left"><a style="left: 0%;" class="ui-slider-handle ui-state-default ui-corner-all" href="#"></a><a style="left: 50%;" class="ui-slider-handle ui-state-default ui-corner-all" href="#"></a></div><p></p><input id="showonlyupdated" name="osu" type="checkbox"><label for="showonlyupdated" style="font-size: x-small;">Show only changed items</label></div><br><div class="demo"><p><label for="amount">Enrollment:</label><input name="enroll" id="amount" style="border: 0px none; color: rgb(246, 147, 31); font-weight: bold;" value="0 - 2200" autocomplete="off" type="text"></p><div class="ui-slider ui-slider-horizontal ui-widget ui-widget-content ui-corner-all" id="slider-range" align="left"><div style="left: 0%; width: 100%;" class="ui-slider-range ui-widget-header"></div><a style="left: 0%;" class="ui-slider-handle ui-state-default ui-corner-all" href="#"></a><a style="left: 100%;" class="ui-slider-handle ui-state-default ui-corner-all" href="#"></a></div><p></p></div><br><input id="ipwnd" name="ipwnd" type="checkbox"><label style="font-size: x-small;" for="ipwnd">Include  products with no data</label></td></tr><tr><td class="bottom">&nbsp;</td><td class="bottom">&nbsp;</td><td class="bottom">&nbsp;</td><td class="bottom">&nbsp;</td><td class="bottom">&nbsp;</td><td class="right bottom"><div id="menuwrapper" style="vertical-align: bottom; margin-left: 2px;"><ul><li class="arrow" style="height: 23px;"><a href="javascript:%20void(0);">Select Products</a><ul id="productbox"><li><a href="javascript:%20void(0);"><input value="12" id="product_12" class="product" style="margin-right: 5px;" type="checkbox">AG011 / <i>ActoGeniX</i></a></li><li><a href="javascript:%20void(0);"><input value="27" id="product_27" class="product" style="margin-right: 5px;" type="checkbox">AJM300 / <i>Ajinomoto</i></a></li><li><a href="javascript:%20void(0);"><input value="20" id="product_20" class="product" style="margin-right: 5px;" type="checkbox">alicaforsen (ISIS-2302) / <i>Isis, Atlantic Healthcare</i></a></li><li><a href="javascript:%20void(0);"><input value="13" id="product_13" class="product" style="margin-right: 5px;" type="checkbox">AMG 181 / <i>AstraZeneca, Amgen</i></a></li><li><a href="javascript:%20void(0);"><input value="26" id="product_26" class="product" style="margin-right: 5px;" type="checkbox">ASP3291 / <i>Drais</i></a></li><li><a href="javascript:%20void(0);"><input value="15" id="product_15" class="product" style="margin-right: 5px;" type="checkbox">ATR-107, PF-05230900 / <i>Pfizer</i></a></li><li><a href="javascript:%20void(0);"><input value="16" id="product_16" class="product" style="margin-right: 5px;" type="checkbox">baminercept (BG9924, LTβR-Ig) / <i>Biogen Idec</i></a></li><li><a href="javascript:%20void(0);"><input value="31" id="product_31" class="product" style="margin-right: 5px;" type="checkbox">BAY 86-5311 / <i>Bayer</i></a></li><li><a href="javascript:%20void(0);"><input value="6" id="product_6" class="product" style="margin-right: 5px;" type="checkbox">BMS-936557 / <i>BMS</i></a></li><li><a href="javascript:%20void(0);"><input value="10" id="product_10" class="product" style="margin-right: 5px;" type="checkbox">brodalumab (AMG 827) / <i>AstraZeneca, Amgen, Kyowa Hakko Kirin</i></a></li><li><a href="javascript:%20void(0);"><input value="25" id="product_25" class="product" style="margin-right: 5px;" type="checkbox">E6007 / <i>Eisai</i></a></li><li><a href="javascript:%20void(0);"><input value="5" id="product_5" class="product" style="margin-right: 5px;" type="checkbox">etrolizumab (rhuMAb Beta7, RG7413) / <i>Roche</i></a></li><li><a href="javascript:%20void(0);"><input value="24" id="product_24" class="product" style="margin-right: 5px;" type="checkbox">firategrast (SB683699, T0047) / <i>GSK</i></a></li><li><a href="javascript:%20void(0);"><input value="30" id="product_30" class="product" style="margin-right: 5px;" type="checkbox">FX003 / <i>Flexion</i></a></li><li><a href="javascript:%20void(0);"><input value="14" id="product_14" class="product" style="margin-right: 5px;" type="checkbox">GSK1070806 / <i>GSK</i></a></li><li><a href="javascript:%20void(0);"><input value="21" id="product_21" class="product" style="margin-right: 5px;" type="checkbox">GSK 1399686 / <i>GSK</i></a></li><li><a href="javascript:%20void(0);"><input value="8" id="product_8" class="product" style="margin-right: 5px;" type="checkbox">HMPL-004 / <i>Hutchinson Medipharma</i></a></li><li><a href="javascript:%20void(0);"><input value="28" id="product_28" class="product" style="margin-right: 5px;" type="checkbox">NV-52, NV 07β / <i>Novogen</i></a></li><li><a href="javascript:%20void(0);"><input value="4" id="product_4" class="product" style="margin-right: 5px;" type="checkbox">Orencia (abatacept) / <i>Ono, BMS</i></a></li><li><a href="javascript:%20void(0);"><input value="7" id="product_7" class="product" style="margin-right: 5px;" type="checkbox">PF-547659, MAdCAM Mab / <i>Pfizer</i></a></li><li><a href="javascript:%20void(0);"><input value="0" id="product_0" class="product" style="margin-right: 5px;" type="checkbox">Prochymal (remestemcel-L, JR-031, Provacel) / <i>Osiris</i></a></li><li><a href="javascript:%20void(0);"><input value="29" id="product_29" class="product" style="margin-right: 5px;" type="checkbox">R 1541 / <i>Roche</i></a></li><li><a href="javascript:%20void(0);"><input value="11" id="product_11" class="product" style="margin-right: 5px;" type="checkbox">secukinumab (AIN 457A) / <i>Novartis</i></a></li><li><a href="javascript:%20void(0);"><input value="3" id="product_3" class="product" style="margin-right: 5px;" type="checkbox">Simponi (golimumab) / <i>J&amp;J/Janssen Biotech, Merck</i></a></li><li><a href="javascript:%20void(0);"><input value="22" id="product_22" class="product" style="margin-right: 5px;" type="checkbox">sotrastaurin (NVP AEB071) / <i>Novartis</i></a></li><li><a href="javascript:%20void(0);"><input value="1" id="product_1" class="product" style="margin-right: 5px;" type="checkbox">Stelara (ustekinumab) / <i>J&amp;J/Centocor Ortho Biotech, BMS/Medarex</i></a></li><li><a href="javascript:%20void(0);"><input value="19" id="product_19" class="product" style="margin-right: 5px;" type="checkbox">tetomilast (OPC-6535) / <i>Otsuka</i></a></li><li><a href="javascript:%20void(0);"><input value="17" id="product_17" class="product" style="margin-right: 5px;" type="checkbox">tofacitinib, tasocitinib (CP-690550) / <i>Pfizer</i></a></li><li><a href="javascript:%20void(0);"><input value="9" id="product_9" class="product" style="margin-right: 5px;" type="checkbox">Vatelizumab (GBR 500) / <i>Glenmark, Sanofi</i></a></li><li><a href="javascript:%20void(0);"><input value="2" id="product_2" class="product" style="margin-right: 5px;" type="checkbox">vedolizumab (LDP 02, MLN 0002, MLN02) / <i>Takeda</i></a></li><li><a href="javascript:%20void(0);"><input value="18" id="product_18" class="product" style="margin-right: 5px;" type="checkbox">vercirnon (Traficet-EN, CCX282-B, GSK1605786) / <i>GSK, ChemoCentryx</i></a></li><li><a href="javascript:%20void(0);"><input value="23" id="product_23" class="product" style="margin-right: 5px;" type="checkbox">vidofludimus (4SC101, SC12267) / <i>4SC</i></a></li></ul></li></ul></div></td></tr><tr><td colspan="5" style="border: medium none; height: 29px;"></td></tr></tbody></table><input name="status" id="status" value="" type="hidden"><input name="itype" id="itype" value="0" type="hidden"><input name="region" id="region" value="" type="hidden"><input name="phase" id="phase" value="" type="hidden"><div style="width: 1307px;" id="parent"><div style="" class="advanced" id="togglefilters"><img src="funnel.png" alt="Show Filter" style="vertical-align: bottom;">&nbsp;Advanced</div><div style="" class="records">38&nbsp;Trials</div><div style="width: 559px;" class="mCustomScrollbar _mCS_1" id="outercontainer"><div class="mCustomScrollBox mCSB_horizontal" id="mCSB_1" style="position: relative; height: 100%; overflow: hidden; max-width: 100%;"><div class="mCSB_container mCS_no_scrollbar" style="position: relative; left: 0px; width: 15px;"><p style="overflow: hidden; margin: 0px;"><span class="filters"><label>Industry lead sponsor</label><a href="http://www.larvoltrials.com/intermediary.php?p=4108%2C2082%2C3514%2C2976%2C4163%2C3191%2C4365%2C1580%2C255%2C2778%2C3615%2C1887%2C4101%2C462%2C3509%2C4473%2C3060%2C1599%2C2399%2C205%2C2183%2C1159%2C2034%2C3256%2C1442%2C572%2C1038%2C3607%2C3407%2C1392%2C3168%2C2835&amp;a=4&amp;sr=now&amp;er=1+month&amp;itype=&amp;LI=1&amp;hm=179&amp;minenroll=0&amp;maxenroll=0&amp;rlink=%2Clist%3D1%2Citype%3D0%2Chm%3D179&amp;rflag=1"><img src="black-cancel.png" alt="Remove Filter"></a></span></p></div><div class="mCSB_scrollTools" style="position: absolute; display: none;"><div class="mCSB_draggerContainer" style="position: relative;"><div class="mCSB_dragger ui-draggable" style="position: relative; width: 0px; left: 0px;"><div class="mCSB_dragger_bar" style="position: relative;"></div></div><div class="mCSB_draggerRail"></div></div></div></div></div><div style="" id="fulltextsearchbox"><input name="ss" autocomplete="off" style="width: 153px;" value="" type="text"></div><div style="" id="buttons"><input id="Show" value="Search" class="searchbutton" type="submit">&nbsp;<a style="display: inline;" href="http://larvoltrials.com/intermediary.php?p=4108,2082,3514,2976,4163,3191,4365,1580,255,2778,3615,1887,4101,462,3509,4473,3060,1599,2399,205,2183,1159,2034,3256,1442,572,1038,3607,3407,1392,3168,2835&amp;a=4&amp;list=1&amp;itype=0&amp;hm=179"><input value="Reset" id="reset" class="resetbutton" onclick="javascript: window.location.href('http://larvoltrials.com/intermediary.php?p=4108,2082,3514,2976,4163,3191,4365,1580,255,2778,3615,1887,4101,462,3509,4473,3060,1599,2399,205,2183,1159,2034,3256,1442,572,1038,3607,3407,1392,3168,2835&amp;a=4&amp;list=1&amp;itype=0&amp;hm=179')" type="button"></a></div><div class="milestones" style="width: 155px; margin-right: 10px;"><div id="addtoright"></div><div style="background-image: url('up.png'); background-repeat: no-repeat; background-position: left center; border: 1px solid; padding: 2px; cursor: pointer;" id="addedtoright">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Show all milestones</b></div></div><div class="export" id="chromemenu" style="width: 64px;"><div><a rel="dropmenu"><b style="margin-left: 16px;">Export</b> </a></div></div></div><input name="rflag" value="1" type="hidden"><input name="rlink" value=",list=1,itype=0,hm=179" type="hidden"><table style="" class="manage" cellpadding="0" cellspacing="0"><tbody><tr><th style="width: 70px;">ID</th><th style="width: 270px;">Title</th><th style="width: 30px;" title="Red: Change greater than 20%">N</th><th style="width: 64px;" title="&quot;RoW&quot; = Rest of World">Region</th><th style="width: 100px;">Interventions</th><th style="width: 90px;">Sponsor</th><th style="width: 105px;">Status</th><th style="width: 100px;">Conditions</th><th title="MM/YY" style="width: 33px;">End</th><th style="width: 25px;">Ph</th><th style="width: 25px;">Res</th><th colspan="3" style="width: 12px;">-</th><th colspan="12" style="width: 32px;">2012</th><th colspan="12" style="width: 32px;">2013</th><th colspan="12" style="width: 32px;">2014</th><th colspan="3" style="width: 12px;">+</th></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bProchymalbreme');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Prochymal</b> (remestemcel-L, JR-031, Provacel) / <i>Osiris</i></td></tr><tr style="display: none;" class="upms bProchymalbreme"><td><a href="http://larvoltrials.com/upm.php?search_id=1147" target="_top">1147</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=32764d4c-5a2b-4392-a3fb-aa079e6a3886&amp;ts=634723986135396448" target="_top">Decision by Health Canada</a></div></td><td><div class="rowcollapse">Pending</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">05/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="Decision by Health Canada"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=32764d4c-5a2b-4392-a3fb-aa079e6a3886&amp;ts=634723986135396448" target="_top"><img src="hourglass.png" alt="Hourglass" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="May 2012 - May 2012 Decision by Health Canada"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=32764d4c-5a2b-4392-a3fb-aa079e6a3886&amp;ts=634723986135396448" target="_top">&nbsp;</a></div></td><td style="width: 8px;" class="" colspan="4"><div title="May 2012 - May 2012 Decision by Health Canada"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=32764d4c-5a2b-4392-a3fb-aa079e6a3886&amp;ts=634723986135396448" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="May 2012 - May 2012 Decision by Health Canada"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=32764d4c-5a2b-4392-a3fb-aa079e6a3886&amp;ts=634723986135396448" target="_top">&nbsp;</a></div></td><td style="width: 14px;" colspan="7"><div title="May 2012 - May 2012 Decision by Health Canada"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=32764d4c-5a2b-4392-a3fb-aa079e6a3886&amp;ts=634723986135396448" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2012 - May 2012 Decision by Health Canada"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=32764d4c-5a2b-4392-a3fb-aa079e6a3886&amp;ts=634723986135396448" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2012 - May 2012 Decision by Health Canada"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=32764d4c-5a2b-4392-a3fb-aa079e6a3886&amp;ts=634723986135396448" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="May 2012 - May 2012 Decision by Health Canada"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=32764d4c-5a2b-4392-a3fb-aa079e6a3886&amp;ts=634723986135396448" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bProchymalbreme"><td><a href="http://larvoltrials.com/upm.php?search_id=5279" target="_top">5279</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">P2 trial completion</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">12/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" class="" colspan="3"><div title="Jan 2012 - Dec 2012 P2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2012 - Dec 2012 P2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2012 - Dec 2012 P2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2012 - Dec 2012 P2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2012 - Dec 2012 P2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bProchymalbreme"><td><a href="http://larvoltrials.com/upm.php?search_id=1151" target="_top">1151</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">P2 data</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">12/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Dec 2013 P2 data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2013 - Dec 2013 P2 data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2013 - Dec 2013 P2 data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2013 - Dec 2013 P2 data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Dec 2013 P2 data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c23b9c3d-14be-434f-8627-955539ce2267&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=112623" target="_top">1233960</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01233960" target="_top" onclick="INC_ViewCount(112623)"><font id="ViewCount_112623"></font>Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">120</div></td><td rowspan="1" class="title "><div class="rowcollapse">US</div></td><td rowspan="1" class="title "><div class="rowcollapse">adult human mesenchymal stem cells, Prochymal, remestemcel-L</div></td><td rowspan="1" class="title "><div class="rowcollapse">Osiris Therapeutics </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">06/13</div></td><td rowspan="1" class="title "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td style="width: 42px; background-color: rgb(255, 153, 0);" colspan="21" title="Sep 2010 - Jun 2013">&nbsp;</td><td style="width: 12px;" colspan="6">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=55503" target="_top">482092</a></div></td><td rowspan="2" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT00482092" target="_top" onclick="INC_ViewCount(55503)"><font id="ViewCount_55503"><span class="viewcount" title="Total views">2&nbsp;</span>&nbsp;</font>Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease</a></div></td><td rowspan="2" class="alttitle " nowrap="nowrap"><div class="rowcollapse">270</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">US, Canada</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">adult human mesenchymal stem cells, Placebo</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Osiris Therapeutics </div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">12/14</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td style="width: 78px; background-color: rgb(255, 153, 0);" colspan="39" title="May 2007 - Dec 2014">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td style="border-top: 0px none;" class="alttitle"><a style="color: gray;" href="http://larvoltrials.com/upm.php?search_id=1146" target="_top">1146</a></td><td style="text-align: center; vertical-align: middle;"><div p3="" data="" for="" prochymal="" in="" relapsed="" refractory="" crohn’s="" disease="">&nbsp;</div></td><td style="width: 6px;" class="" colspan="3"><div title="Jan 2012 - Dec 2012 P3 data for Prochymal in relapsed/refractory Crohn’s Disease"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=46ded5ac-2f86-43d7-9daa-b35bbff3c098" target="_top">&nbsp;</a></div></td><td onclick="INC_ViewCount(55503)" style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2012 - Dec 2012 P3 data for Prochymal in relapsed/refractory Crohn’s Disease"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=46ded5ac-2f86-43d7-9daa-b35bbff3c098" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2012 - Dec 2012 P3 data for Prochymal in relapsed/refractory Crohn’s Disease"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=46ded5ac-2f86-43d7-9daa-b35bbff3c098" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2012 - Dec 2012 P3 data for Prochymal in relapsed/refractory Crohn’s Disease"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=46ded5ac-2f86-43d7-9daa-b35bbff3c098" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2012 - Dec 2012 P3 data for Prochymal in relapsed/refractory Crohn’s Disease"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=46ded5ac-2f86-43d7-9daa-b35bbff3c098" target="_top">&nbsp;</a></div></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=133781" target="_top">1510431</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01510431" target="_top" onclick="INC_ViewCount(133781)"><font id="ViewCount_133781"></font>Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">10</div></td><td rowspan="1" class="title "><div class="rowcollapse">US</div></td><td rowspan="1" class="title "><div class="rowcollapse">PROCHYMAL (remestemcel-L)</div></td><td rowspan="1" class="title "><div class="rowcollapse">Osiris Therapeutics </div></td><td rowspan="1" class="title "><div class="rowcollapse">Enrolling by invitation</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">04/14</div></td><td rowspan="1" class="title "><div class="rowcollapse">N/A</div></td><td class="">&nbsp;</td><td style="width: 62px; background-color: rgb(191, 191, 191);" colspan="31" title="May 2009 - Apr 2014">&nbsp;</td><td style="width: 16px;" colspan="8">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bStelarabusteki');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Stelara</b> (ustekinumab) / <i>J&amp;J/Centocor Ortho Biotech, BMS/Medarex</i></td></tr><tr style="display: none;" class="upms bStelarabusteki"><td><a href="http://larvoltrials.com/upm.php?search_id=3975" target="_top">3975</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://newpublic.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3c642b9e-20aa-455d-8298-8426bcd328d7" target="_top">Regulatory submission in US, psoriatic arthritis</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class="">&nbsp;</td><td style="width: 78px; background-color: rgb(153, 102, 255);" colspan="39"><div title="Jan 2011 - Dec 2014 Regulatory submission in US, psoriatic arthritis"><a href="http://newpublic.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3c642b9e-20aa-455d-8298-8426bcd328d7" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2011 - Dec 2014 Regulatory submission in US, psoriatic arthritis"><a href="http://newpublic.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3c642b9e-20aa-455d-8298-8426bcd328d7" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bStelarabusteki"><td><a href="http://larvoltrials.com/upm.php?search_id=3977" target="_top">3977</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">US Launch in CD</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 US Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2014 - Dec 2014 US Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2014 - Dec 2014 US Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2014 - Dec 2014 US Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 US Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bStelarabusteki"><td><a href="http://larvoltrials.com/upm.php?search_id=3979" target="_top">3979</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">EU Launch in CD</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 EU Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2014 - Dec 2014 EU Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2014 - Dec 2014 EU Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2014 - Dec 2014 EU Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 EU Launch in CD"><a href="http://www.prnewswire.com/news-releases/despite-minimal-uptake-in-the-crohns-disease-drug-market-stelaras-premium-price-will-result-in-sales-of-nearly-337-million-in-2018-84945502.html" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bStelarabusteki"><td><a href="http://larvoltrials.com/upm.php?search_id=3976" target="_top">3976</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=11edc972-b38d-4fda-94fb-e1afbc73d622" target="_top">Filing for Crohn’s disease</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/15</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(153, 102, 255);"><div title="Jan 2011 - Dec 2015 Filing for Crohn’s disease"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=11edc972-b38d-4fda-94fb-e1afbc73d622" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bStelarabusteki"><td><a href="http://larvoltrials.com/upm.php?search_id=3363" target="_top">3363</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=093f00dc-974a-486f-9f3e-4c56d25d8141" target="_top">Patent expiry in Europe</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/21</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2021 - Dec 2021 Patent expiry in Europe"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=093f00dc-974a-486f-9f3e-4c56d25d8141" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2021 - Dec 2021 Patent expiry in Europe"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=093f00dc-974a-486f-9f3e-4c56d25d8141" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2021 - Dec 2021 Patent expiry in Europe"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=093f00dc-974a-486f-9f3e-4c56d25d8141" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2021 - Dec 2021 Patent expiry in Europe"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=093f00dc-974a-486f-9f3e-4c56d25d8141" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2021 - Dec 2021 Patent expiry in Europe"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=093f00dc-974a-486f-9f3e-4c56d25d8141" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bStelarabusteki"><td><a href="http://larvoltrials.com/upm.php?search_id=923" target="_top">923</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">EU patent expiry</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/21</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2021 - Dec 2021 EU patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2021 - Dec 2021 EU patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2021 - Dec 2021 EU patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2021 - Dec 2021 EU patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2021 - Dec 2021 EU patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bStelarabusteki"><td><a href="http://larvoltrials.com/upm.php?search_id=924" target="_top">924</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">US patent expiry</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">09/22</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Apr 2022 - Sep 2022 US patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2022 - Sep 2022 US patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2022 - Sep 2022 US patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Apr 2022 - Sep 2022 US patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Apr 2022 - Sep 2022 US patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c9c10d0f-2a5e-40e0-a5d9-0cbed69db408&amp;ts=634578059954131776" target="_top">&nbsp;</a></div></td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=122976" target="_top">1369329</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01369329" target="_top" onclick="INC_ViewCount(122976)"><font id="ViewCount_122976"></font>A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">703</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C. </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">10/13</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td style="width: 50px; background-color: rgb(255, 153, 0);" colspan="25" title="Jun 2011 - Oct 2013">&nbsp;</td><td style="width: 4px;" colspan="2">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=122977" target="_top">1369342</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01369342" target="_top" onclick="INC_ViewCount(122977)"><font id="ViewCount_122977"></font>A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">612</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo, Group 2 ustekinumab 130 mg</div></td><td rowspan="1" class="title "><div class="rowcollapse">Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C. </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis</div></td><td rowspan="1" class="title "><div class="rowcollapse">06/14</div></td><td rowspan="1" class="title "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td style="width: 66px; background-color: rgb(255, 153, 0);" colspan="33" title="Feb 2011 - Jun 2014">&nbsp;</td><td style="width: 12px;" colspan="6">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=122978" target="_top">1369355</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01369355" target="_top" onclick="INC_ViewCount(122978)"><font id="ViewCount_122978"></font>A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">1310</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Placebo, Ustekinumab</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C. </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Enrolling by invitation</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">09/18</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 153, 0);" title="Jul 2011 - Sep 2018">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bvedolizumabbLD');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>vedolizumab</b> (LDP 02, MLN 0002, MLN02) / <i>Takeda</i></td></tr><tr style="display: none;" class="upms bvedolizumabbLD"><td><a href="http://larvoltrials.com/upm.php?search_id=5281" target="_top">5281</a></td><td colspan="5" class=" highlight" title="Previous value: Launch"><div class="rowcollapse"><a style="color: rgb(255, 0, 0);" href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ae202a80-92b7-4dc6-8f10-acd41f569eb2&amp;ts=634664399204456760" target="_top">Market launch (IBD)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">09/15</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jul 2015 - Sep 2015 Market launch (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ae202a80-92b7-4dc6-8f10-acd41f569eb2&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2015 - Sep 2015 Market launch (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ae202a80-92b7-4dc6-8f10-acd41f569eb2&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2015 - Sep 2015 Market launch (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ae202a80-92b7-4dc6-8f10-acd41f569eb2&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jul 2015 - Sep 2015 Market launch (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ae202a80-92b7-4dc6-8f10-acd41f569eb2&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jul 2015 - Sep 2015 Market launch (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ae202a80-92b7-4dc6-8f10-acd41f569eb2&amp;ts=634664399204456760" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvedolizumabbLD"><td><a href="http://larvoltrials.com/upm.php?search_id=4011" target="_top">4011</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b95613b4-994a-42c4-b48b-a939a5350343" target="_top">Approval of MLN0002</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/15</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2015 Approval of MLN0002"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b95613b4-994a-42c4-b48b-a939a5350343" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2014 - Dec 2015 Approval of MLN0002"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b95613b4-994a-42c4-b48b-a939a5350343" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2014 - Dec 2015 Approval of MLN0002"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b95613b4-994a-42c4-b48b-a939a5350343" target="_top">&nbsp;</a></div></td><td colspan="15" style="width: 30px; background-color: rgb(153, 102, 255);"><div title="Jan 2014 - Dec 2015 Approval of MLN0002"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b95613b4-994a-42c4-b48b-a939a5350343" target="_top">&nbsp;</a></div></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=78907" target="_top">NCT00790933
2008-002784-14</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT00790933" target="_top" onclick="INC_ViewCount(78907)"><font id="ViewCount_78907"><span class="viewcount" title="Total views">2&nbsp;</span>&nbsp;</font>GEMINI LTS An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">2200</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Canada, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">vedolizumab, MLN0002</div></td><td rowspan="1" class="title "><div class="rowcollapse">Millennium Pharmaceuticals, Inc. </div></td><td rowspan="1" class="title highlight" title="Previous value: Recruiting"><div class="rowcollapse">Active, not recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Ulcerative Colitis, Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">08/16</div></td><td rowspan="1" class="title "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 153, 0);" title="May 2009 - Aug 2016">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bSimponibgolimu');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Simponi</b> (golimumab) / <i>J&amp;J/Janssen Biotech, Merck</i></td></tr><tr style="display: none;" class="upms bSimponibgolimu"><td><a href="http://larvoltrials.com/upm.php?search_id=7412" target="_top">7412</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f8cbb371-b3e8-440b-ad81-08b656167998&amp;ts=634783792724081250" target="_top">BLA and EMA (type II variation) submission (moderate to severe active UC)</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">07/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="BLA and EMA (type II variation) submission (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f8cbb371-b3e8-440b-ad81-08b656167998&amp;ts=634783792724081250" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Jul 2012 BLA and EMA (type II variation) submission (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f8cbb371-b3e8-440b-ad81-08b656167998&amp;ts=634783792724081250" target="_top">&nbsp;</a></div></td><td style="width: 12px;" class="" colspan="6"><div title="Jul 2012 - Jul 2012 BLA and EMA (type II variation) submission (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f8cbb371-b3e8-440b-ad81-08b656167998&amp;ts=634783792724081250" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);"><div title="Jul 2012 - Jul 2012 BLA and EMA (type II variation) submission (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f8cbb371-b3e8-440b-ad81-08b656167998&amp;ts=634783792724081250" target="_top">&nbsp;</a></div></td><td style="width: 10px;" colspan="5"><div title="Jul 2012 - Jul 2012 BLA and EMA (type II variation) submission (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f8cbb371-b3e8-440b-ad81-08b656167998&amp;ts=634783792724081250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2012 - Jul 2012 BLA and EMA (type II variation) submission (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f8cbb371-b3e8-440b-ad81-08b656167998&amp;ts=634783792724081250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2012 - Jul 2012 BLA and EMA (type II variation) submission (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f8cbb371-b3e8-440b-ad81-08b656167998&amp;ts=634783792724081250" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Jul 2012 BLA and EMA (type II variation) submission (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f8cbb371-b3e8-440b-ad81-08b656167998&amp;ts=634783792724081250" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bSimponibgolimu"><td><a href="http://larvoltrials.com/upm.php?search_id=7430" target="_top">7430</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=85fdd01f-d9e7-4b8d-8d56-719c13b0d858&amp;ts=634826697892112500" target="_top">FDA approval (moderate to severe active UC)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">03/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Mar 2013 FDA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=85fdd01f-d9e7-4b8d-8d56-719c13b0d858&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2013 - Mar 2013 FDA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=85fdd01f-d9e7-4b8d-8d56-719c13b0d858&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Jan 2013 - Mar 2013 FDA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=85fdd01f-d9e7-4b8d-8d56-719c13b0d858&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 18px;" colspan="9"><div title="Jan 2013 - Mar 2013 FDA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=85fdd01f-d9e7-4b8d-8d56-719c13b0d858&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2013 - Mar 2013 FDA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=85fdd01f-d9e7-4b8d-8d56-719c13b0d858&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Mar 2013 FDA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=85fdd01f-d9e7-4b8d-8d56-719c13b0d858&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bSimponibgolimu"><td><a href="http://larvoltrials.com/upm.php?search_id=7431" target="_top">7431</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634784592397595000" target="_top">EMA approval (moderate to severe active UC)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">06/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Apr 2013 - Jun 2013 EMA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634784592397595000" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2013 - Jun 2013 EMA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634784592397595000" target="_top">&nbsp;</a></div></td><td style="width: 6px;" class="" colspan="3"><div title="Apr 2013 - Jun 2013 EMA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634784592397595000" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Apr 2013 - Jun 2013 EMA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634784592397595000" target="_top">&nbsp;</a></div></td><td style="width: 12px;" colspan="6"><div title="Apr 2013 - Jun 2013 EMA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634784592397595000" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2013 - Jun 2013 EMA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634784592397595000" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Apr 2013 - Jun 2013 EMA approval (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634784592397595000" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bSimponibgolimu"><td><a href="http://larvoltrials.com/upm.php?search_id=7411" target="_top">7411</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634783792723925000" target="_top">Drug launch (moderate to severe active UC)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">06/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Apr 2013 - Jun 2013 Drug launch (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634783792723925000" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2013 - Jun 2013 Drug launch (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634783792723925000" target="_top">&nbsp;</a></div></td><td style="width: 6px;" class="" colspan="3"><div title="Apr 2013 - Jun 2013 Drug launch (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634783792723925000" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Apr 2013 - Jun 2013 Drug launch (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634783792723925000" target="_top">&nbsp;</a></div></td><td style="width: 12px;" colspan="6"><div title="Apr 2013 - Jun 2013 Drug launch (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634783792723925000" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2013 - Jun 2013 Drug launch (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634783792723925000" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Apr 2013 - Jun 2013 Drug launch (moderate to severe active UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=54b155d2-fdba-4643-bb14-6378a1312d6f&amp;ts=634783792723925000" target="_top">&nbsp;</a></div></td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=55999" target="_top">488631</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT00488631" target="_top" onclick="INC_ViewCount(55999)"><font id="ViewCount_55999"></font>A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014179)</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">1228</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Golimumab, placebo, golimumab, placebo, Placebo</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Centocor, Inc. Schering-Plough</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Active, not recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">06/17</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 153, 0);" title="Jan 2007 - Jun 2017">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bOrenciababatac');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Orencia</b> (abatacept) / <i>Ono, BMS</i></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=4008" target="_top">4008</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a40b66d0-08ee-4c2b-9a09-5d521b8658e8" target="_top">FDA action date</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">07/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="FDA action date"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=398fef6c-b4e0-4534-b393-9f74b0a39779" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jul 2011 - Jul 2011 FDA action date"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a40b66d0-08ee-4c2b-9a09-5d521b8658e8" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2011 - Jul 2011 FDA action date"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a40b66d0-08ee-4c2b-9a09-5d521b8658e8" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2011 - Jul 2011 FDA action date"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a40b66d0-08ee-4c2b-9a09-5d521b8658e8" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2011 - Jul 2011 FDA action date"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a40b66d0-08ee-4c2b-9a09-5d521b8658e8" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2011 - Jul 2011 FDA action date"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a40b66d0-08ee-4c2b-9a09-5d521b8658e8" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=5628" target="_top">5628</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=69aa3a22-15f4-46a8-b180-4ae63c861f24&amp;ts=634683054182452859" target="_top">P3 data (AIM)</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">03/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=69aa3a22-15f4-46a8-b180-4ae63c861f24&amp;ts=634683054182452859" target="_top"><img src="black-diamond.png" alt="Diamond" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=69aa3a22-15f4-46a8-b180-4ae63c861f24&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 4px;" class="" colspan="2"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=69aa3a22-15f4-46a8-b180-4ae63c861f24&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=69aa3a22-15f4-46a8-b180-4ae63c861f24&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 18px;" colspan="9"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=69aa3a22-15f4-46a8-b180-4ae63c861f24&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=69aa3a22-15f4-46a8-b180-4ae63c861f24&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=69aa3a22-15f4-46a8-b180-4ae63c861f24&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=69aa3a22-15f4-46a8-b180-4ae63c861f24&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=5629" target="_top">5629</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=06d8ca2c-e715-488d-8a6f-482c7a0e454d&amp;ts=634683054182452859" target="_top">P3 data (AIM)</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">03/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=06d8ca2c-e715-488d-8a6f-482c7a0e454d&amp;ts=634683054182452859" target="_top"><img src="black-diamond.png" alt="Diamond" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=06d8ca2c-e715-488d-8a6f-482c7a0e454d&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 4px;" class="" colspan="2"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=06d8ca2c-e715-488d-8a6f-482c7a0e454d&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=06d8ca2c-e715-488d-8a6f-482c7a0e454d&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 18px;" colspan="9"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=06d8ca2c-e715-488d-8a6f-482c7a0e454d&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=06d8ca2c-e715-488d-8a6f-482c7a0e454d&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=06d8ca2c-e715-488d-8a6f-482c7a0e454d&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Mar 2012 - Mar 2012 P3 data (AIM)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=06d8ca2c-e715-488d-8a6f-482c7a0e454d&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=5630" target="_top">5630</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e980537e-198a-45bd-bb77-79ca7c3c0047&amp;ts=634683054182452859" target="_top">Data (ACTION)</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">03/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="Data (ACTION)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e980537e-198a-45bd-bb77-79ca7c3c0047&amp;ts=634683054182452859" target="_top"><img src="black-diamond.png" alt="Diamond" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Mar 2012 - Mar 2012 Data (ACTION)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e980537e-198a-45bd-bb77-79ca7c3c0047&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 4px;" class="" colspan="2"><div title="Mar 2012 - Mar 2012 Data (ACTION)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e980537e-198a-45bd-bb77-79ca7c3c0047&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);"><div title="Mar 2012 - Mar 2012 Data (ACTION)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e980537e-198a-45bd-bb77-79ca7c3c0047&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 18px;" colspan="9"><div title="Mar 2012 - Mar 2012 Data (ACTION)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e980537e-198a-45bd-bb77-79ca7c3c0047&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Mar 2012 - Mar 2012 Data (ACTION)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e980537e-198a-45bd-bb77-79ca7c3c0047&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Mar 2012 - Mar 2012 Data (ACTION)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e980537e-198a-45bd-bb77-79ca7c3c0047&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Mar 2012 - Mar 2012 Data (ACTION)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e980537e-198a-45bd-bb77-79ca7c3c0047&amp;ts=634683054182452859" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=7364" target="_top">7364</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=207be2c9-551c-4e19-9e0e-4b3a9064e4f5&amp;ts=634779840769432500" target="_top">Filing in Japan (RA) (SC)</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">07/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="Filing in Japan (RA) (SC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=207be2c9-551c-4e19-9e0e-4b3a9064e4f5&amp;ts=634779840769432500" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Jul 2012 Filing in Japan (RA) (SC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=207be2c9-551c-4e19-9e0e-4b3a9064e4f5&amp;ts=634779840769432500" target="_top">&nbsp;</a></div></td><td style="width: 12px;" class="" colspan="6"><div title="Jul 2012 - Jul 2012 Filing in Japan (RA) (SC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=207be2c9-551c-4e19-9e0e-4b3a9064e4f5&amp;ts=634779840769432500" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Jul 2012 - Jul 2012 Filing in Japan (RA) (SC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=207be2c9-551c-4e19-9e0e-4b3a9064e4f5&amp;ts=634779840769432500" target="_top">&nbsp;</a></div></td><td style="width: 10px;" colspan="5"><div title="Jul 2012 - Jul 2012 Filing in Japan (RA) (SC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=207be2c9-551c-4e19-9e0e-4b3a9064e4f5&amp;ts=634779840769432500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2012 - Jul 2012 Filing in Japan (RA) (SC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=207be2c9-551c-4e19-9e0e-4b3a9064e4f5&amp;ts=634779840769432500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2012 - Jul 2012 Filing in Japan (RA) (SC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=207be2c9-551c-4e19-9e0e-4b3a9064e4f5&amp;ts=634779840769432500" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Jul 2012 Filing in Japan (RA) (SC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=207be2c9-551c-4e19-9e0e-4b3a9064e4f5&amp;ts=634779840769432500" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=6564" target="_top">6564</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e68f5a0d-de92-4949-a048-b9862a397a58&amp;ts=634791306994661250" target="_top">EU approval, SC formulation (RA)</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">10/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="EU approval, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=4a493041-5a73-4954-81a9-32f7a073c97f&amp;ts=634852488970511250" target="_top"><img src="red-checkmark.png" alt="Checkmark" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Oct 2012 - Oct 2012 EU approval, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e68f5a0d-de92-4949-a048-b9862a397a58&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 18px;" class="" colspan="9"><div title="Oct 2012 - Oct 2012 EU approval, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e68f5a0d-de92-4949-a048-b9862a397a58&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Oct 2012 - Oct 2012 EU approval, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e68f5a0d-de92-4949-a048-b9862a397a58&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 4px;" colspan="2"><div title="Oct 2012 - Oct 2012 EU approval, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e68f5a0d-de92-4949-a048-b9862a397a58&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2012 - Oct 2012 EU approval, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e68f5a0d-de92-4949-a048-b9862a397a58&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2012 - Oct 2012 EU approval, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e68f5a0d-de92-4949-a048-b9862a397a58&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Oct 2012 - Oct 2012 EU approval, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e68f5a0d-de92-4949-a048-b9862a397a58&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=7516" target="_top">7516</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7f96a33d-6f89-4ac9-8885-7810655d9dab&amp;ts=634791306994661250" target="_top">Launch in Europe, SC formulation (RA)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Oct 2012 - Dec 2012 Launch in Europe, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7f96a33d-6f89-4ac9-8885-7810655d9dab&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 18px;" class="" colspan="9"><div title="Oct 2012 - Dec 2012 Launch in Europe, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7f96a33d-6f89-4ac9-8885-7810655d9dab&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Oct 2012 - Dec 2012 Launch in Europe, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7f96a33d-6f89-4ac9-8885-7810655d9dab&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2012 - Dec 2012 Launch in Europe, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7f96a33d-6f89-4ac9-8885-7810655d9dab&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2012 - Dec 2012 Launch in Europe, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7f96a33d-6f89-4ac9-8885-7810655d9dab&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Oct 2012 - Dec 2012 Launch in Europe, SC formulation (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7f96a33d-6f89-4ac9-8885-7810655d9dab&amp;ts=634791306994661250" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=6563" target="_top">6563</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=82fdee3b-68f1-4dbd-aaf5-1b3e9aa3c0f4&amp;ts=634724602666858315" target="_top">P3 trial initiation (Lupus nephritis and Psoriatic arthritis)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">12/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="May 2012 - Dec 2012 P3 trial initiation (Lupus nephritis and Psoriatic arthritis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=82fdee3b-68f1-4dbd-aaf5-1b3e9aa3c0f4&amp;ts=634724602666858315" target="_top">&nbsp;</a></div></td><td style="width: 8px;" class="" colspan="4"><div title="May 2012 - Dec 2012 P3 trial initiation (Lupus nephritis and Psoriatic arthritis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=82fdee3b-68f1-4dbd-aaf5-1b3e9aa3c0f4&amp;ts=634724602666858315" target="_top">&nbsp;</a></div></td><td style="width: 16px; background-color: rgb(153, 102, 255);" colspan="8"><div title="May 2012 - Dec 2012 P3 trial initiation (Lupus nephritis and Psoriatic arthritis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=82fdee3b-68f1-4dbd-aaf5-1b3e9aa3c0f4&amp;ts=634724602666858315" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2012 - Dec 2012 P3 trial initiation (Lupus nephritis and Psoriatic arthritis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=82fdee3b-68f1-4dbd-aaf5-1b3e9aa3c0f4&amp;ts=634724602666858315" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2012 - Dec 2012 P3 trial initiation (Lupus nephritis and Psoriatic arthritis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=82fdee3b-68f1-4dbd-aaf5-1b3e9aa3c0f4&amp;ts=634724602666858315" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="May 2012 - Dec 2012 P3 trial initiation (Lupus nephritis and Psoriatic arthritis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=82fdee3b-68f1-4dbd-aaf5-1b3e9aa3c0f4&amp;ts=634724602666858315" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=4009" target="_top">4009</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=dcc33bad-7bb6-4d41-9d17-a54c3d2d96a3&amp;ts=634676370798931440" target="_top">Patent expiry in EU</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/17</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2017 - Dec 2017 Patent expiry in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=dcc33bad-7bb6-4d41-9d17-a54c3d2d96a3&amp;ts=634676370798931440" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2017 - Dec 2017 Patent expiry in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=dcc33bad-7bb6-4d41-9d17-a54c3d2d96a3&amp;ts=634676370798931440" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2017 - Dec 2017 Patent expiry in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=dcc33bad-7bb6-4d41-9d17-a54c3d2d96a3&amp;ts=634676370798931440" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2017 - Dec 2017 Patent expiry in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=dcc33bad-7bb6-4d41-9d17-a54c3d2d96a3&amp;ts=634676370798931440" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2017 - Dec 2017 Patent expiry in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=dcc33bad-7bb6-4d41-9d17-a54c3d2d96a3&amp;ts=634676370798931440" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bOrenciababatac"><td><a href="http://larvoltrials.com/upm.php?search_id=4010" target="_top">4010</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=fd01d572-ab0f-4d27-be01-cbff6b0f886d" target="_top">Patent expiry in US</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/19</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2019 - Dec 2019 Patent expiry in US"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=fd01d572-ab0f-4d27-be01-cbff6b0f886d" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2019 - Dec 2019 Patent expiry in US"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=fd01d572-ab0f-4d27-be01-cbff6b0f886d" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2019 - Dec 2019 Patent expiry in US"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=fd01d572-ab0f-4d27-be01-cbff6b0f886d" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2019 - Dec 2019 Patent expiry in US"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=fd01d572-ab0f-4d27-be01-cbff6b0f886d" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2019 - Dec 2019 Patent expiry in US"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=fd01d572-ab0f-4d27-be01-cbff6b0f886d" target="_top">&nbsp;</a></div></td></tr><tr><td colspan="53" class="norecord">No trials found</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'betrolizumabbrh');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>etrolizumab</b> (rhuMAb Beta7, RG7413) / <i>Roche</i></td></tr><tr style="display: none;" class="upms betrolizumabbrh"><td><a href="http://larvoltrials.com/upm.php?search_id=1148" target="_top">1148</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">Decision on P2 initiation, Ulcerative colitis</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">03/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="Decision on P2 initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2011 - Mar 2011 Decision on P2 initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2011 - Mar 2011 Decision on P2 initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2011 - Mar 2011 Decision on P2 initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2011 - Mar 2011 Decision on P2 initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2011 - Mar 2011 Decision on P2 initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms betrolizumabbrh"><td><a href="http://larvoltrials.com/upm.php?search_id=1150" target="_top">1150</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a30463f7-1276-49cd-89cc-ae6a08602892" target="_top">Anticipated P2 enrollment initiation in Ulcerative colitis</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">10/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="Anticipated P2 enrollment initiation in Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a30463f7-1276-49cd-89cc-ae6a08602892" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Oct 2011 - Oct 2011 Anticipated P2 enrollment initiation in Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a30463f7-1276-49cd-89cc-ae6a08602892" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2011 - Oct 2011 Anticipated P2 enrollment initiation in Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a30463f7-1276-49cd-89cc-ae6a08602892" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2011 - Oct 2011 Anticipated P2 enrollment initiation in Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a30463f7-1276-49cd-89cc-ae6a08602892" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2011 - Oct 2011 Anticipated P2 enrollment initiation in Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a30463f7-1276-49cd-89cc-ae6a08602892" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Oct 2011 - Oct 2011 Anticipated P2 enrollment initiation in Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a30463f7-1276-49cd-89cc-ae6a08602892" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms betrolizumabbrh"><td><a href="http://larvoltrials.com/upm.php?search_id=1149" target="_top">1149</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">P2 trial initiation, Ulcerative colitis</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">10/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="P2 trial initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3f5fa8ab-b1ff-48cb-bd00-36c477125685" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Oct 2012 - Oct 2012 P2 trial initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 18px;" class="" colspan="9"><div title="Oct 2012 - Oct 2012 P2 trial initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);"><div title="Oct 2012 - Oct 2012 P2 trial initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 4px;" colspan="2"><div title="Oct 2012 - Oct 2012 P2 trial initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2012 - Oct 2012 P2 trial initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2012 - Oct 2012 P2 trial initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Oct 2012 - Oct 2012 P2 trial initiation, Ulcerative colitis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=479d079a-348d-4a39-90a1-74fcc127533a" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms betrolizumabbrh"><td><a href="http://larvoltrials.com/upm.php?search_id=7886" target="_top">7886</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f19468fc-16b8-4c67-a226-f2344dc69e64&amp;ts=634826697892112500" target="_top">P2 data (UC)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">12/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Sep 2012 - Dec 2012 P2 data (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f19468fc-16b8-4c67-a226-f2344dc69e64&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 16px;" class="" colspan="8"><div title="Sep 2012 - Dec 2012 P2 data (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f19468fc-16b8-4c67-a226-f2344dc69e64&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 8px; background-color: rgb(153, 102, 255);" colspan="4"><div title="Sep 2012 - Dec 2012 P2 data (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f19468fc-16b8-4c67-a226-f2344dc69e64&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Sep 2012 - Dec 2012 P2 data (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f19468fc-16b8-4c67-a226-f2344dc69e64&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Sep 2012 - Dec 2012 P2 data (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f19468fc-16b8-4c67-a226-f2344dc69e64&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Sep 2012 - Dec 2012 P2 data (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=f19468fc-16b8-4c67-a226-f2344dc69e64&amp;ts=634826697892112500" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms betrolizumabbrh"><td><a href="http://larvoltrials.com/upm.php?search_id=4872" target="_top">4872</a></td><td colspan="5" class=" highlight" title="Previous value: http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=4523f7a6-5e94-40a3-8184-fffb0b29fac3&amp;ts=634791436455388750"><div class="rowcollapse"><a style="color: rgb(255, 0, 0);" href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d2a2c261-2661-4b78-918d-2c08635d5f92&amp;ts=634833658242976250" target="_top">Filing (UC)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/17</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2017 - Dec 2017 Filing (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d2a2c261-2661-4b78-918d-2c08635d5f92&amp;ts=634833658242976250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2017 - Dec 2017 Filing (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d2a2c261-2661-4b78-918d-2c08635d5f92&amp;ts=634833658242976250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2017 - Dec 2017 Filing (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d2a2c261-2661-4b78-918d-2c08635d5f92&amp;ts=634833658242976250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2017 - Dec 2017 Filing (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d2a2c261-2661-4b78-918d-2c08635d5f92&amp;ts=634833658242976250" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2017 - Dec 2017 Filing (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d2a2c261-2661-4b78-918d-2c08635d5f92&amp;ts=634833658242976250" target="_top">&nbsp;</a></div></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=120472" target="_top">1336465</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01336465" target="_top" onclick="INC_ViewCount(120472)"><font id="ViewCount_120472"></font>Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">120</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Canada, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">placebo, rhuMAb Beta7</div></td><td rowspan="1" class="title "><div class="rowcollapse">Genentech </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="title "><div class="rowcollapse">01/15</div></td><td rowspan="1" class="title "><div class="rowcollapse">2</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 255, 0);" title="Sep 2011 - Jan 2015">&nbsp;</td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=130015" target="_top">1461317</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01461317" target="_top" onclick="INC_ViewCount(130015)"><font id="ViewCount_130015"></font>Study to Evaluate the Long-term Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">120</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US, Canada, Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">rhuMAb Beta7</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Genentech </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">04/17</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">2</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 255, 0);" title="Nov 2011 - Apr 2017">&nbsp;</td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=71609" target="_top">694980</a></div></td><td rowspan="2" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT00694980" target="_top" onclick="INC_ViewCount(71609)"><font id="ViewCount_71609"></font>A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis</a></div></td><td rowspan="2" class="title " nowrap="nowrap"><div class="rowcollapse">48</div></td><td rowspan="2" class="title "><div class="rowcollapse">US, Canada, Europe</div></td><td rowspan="2" class="title "><div class="rowcollapse">placebo, rhuMAb Beta7</div></td><td rowspan="2" class="title "><div class="rowcollapse">Genentech </div></td><td rowspan="2" class="title "><div class="rowcollapse">Active, not recruiting</div></td><td rowspan="2" class="title "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="2" class="title "><div class="rowcollapse">11/12</div></td><td rowspan="2" class="title "><div class="rowcollapse">1</div></td><td class="">&nbsp;</td><td style="width: 28px; background-color: rgb(153, 204, 0);" colspan="14" title="Sep 2008 - Nov 2012">&nbsp;</td><td style="width: 2px;" colspan="1">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td style="border-top: 0px none;" class="title"><a style="color: gray;" href="http://larvoltrials.com/upm.php?search_id=1861" target="_top">1861</a></td><td class="" style="text-align: center; vertical-align: middle;"><div data=""><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e1f8bceb-51d6-443a-ad6c-e9e602d80d78" target="_top"><img src="black-diamond.png" alt="Diamond" style="padding-top: 3px;" onclick="INC_ViewCount(71609)" border="0"></a></div></td><td onclick="INC_ViewCount(71609)" colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Apr 2011 - Apr 2011 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e1f8bceb-51d6-443a-ad6c-e9e602d80d78" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2011 - Apr 2011 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e1f8bceb-51d6-443a-ad6c-e9e602d80d78" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2011 - Apr 2011 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e1f8bceb-51d6-443a-ad6c-e9e602d80d78" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2011 - Apr 2011 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e1f8bceb-51d6-443a-ad6c-e9e602d80d78" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Apr 2011 - Apr 2011 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e1f8bceb-51d6-443a-ad6c-e9e602d80d78" target="_top">&nbsp;</a></div></td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bBMS936557biBMS');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>BMS-936557</b> / <i>BMS</i></td></tr><tr style="display: none;" class="upms bBMS936557biBMS"><td><a href="http://larvoltrials.com/upm.php?search_id=7551" target="_top">7551</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=56cdc94a-2c9a-41ae-bca3-23465b061999&amp;ts=634791379056951250" target="_top">P2 data in RCC</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">03/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Mar 2013 P2 data in RCC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=56cdc94a-2c9a-41ae-bca3-23465b061999&amp;ts=634791379056951250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2013 - Mar 2013 P2 data in RCC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=56cdc94a-2c9a-41ae-bca3-23465b061999&amp;ts=634791379056951250" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Jan 2013 - Mar 2013 P2 data in RCC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=56cdc94a-2c9a-41ae-bca3-23465b061999&amp;ts=634791379056951250" target="_top">&nbsp;</a></div></td><td style="width: 18px;" colspan="9"><div title="Jan 2013 - Mar 2013 P2 data in RCC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=56cdc94a-2c9a-41ae-bca3-23465b061999&amp;ts=634791379056951250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2013 - Mar 2013 P2 data in RCC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=56cdc94a-2c9a-41ae-bca3-23465b061999&amp;ts=634791379056951250" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Mar 2013 P2 data in RCC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=56cdc94a-2c9a-41ae-bca3-23465b061999&amp;ts=634791379056951250" target="_top">&nbsp;</a></div></td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=117259" target="_top">1294410</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01294410" target="_top" onclick="INC_ViewCount(117259)"><font id="ViewCount_117259"></font>Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">289</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US, Canada, Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Placebo, Anti-IP-10 Antibody</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Bristol-Myers Squibb </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Colitis, Ulcerative</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">03/15</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">2</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 255, 0);" title="Mar 2011 - Mar 2015">&nbsp;</td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=130403" target="_top">1466374</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01466374" target="_top" onclick="INC_ViewCount(130403)"><font id="ViewCount_130403"></font>Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">120</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">Placebo, BMS-936557 (Anti-IP-10 Antibody), Anti-IP-10 Antibody</div></td><td rowspan="1" class="title "><div class="rowcollapse">Bristol-Myers Squibb </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">09/15</div></td><td rowspan="1" class="title "><div class="rowcollapse">2</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 255, 0);" title="Dec 2011 - Sep 2015">&nbsp;</td></tr><tr><td colspan="53" class="sectiontitles"><b>PF-547659, MAdCAM Mab</b> / <i>Pfizer</i></td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=115888" target="_top">1276509</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01276509" target="_top" onclick="INC_ViewCount(115888)"><font id="ViewCount_115888"></font>OPERA Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">240</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US, Canada, Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">PF-00547659 SC injection</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Pfizer </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="alttitle highlight" title="Previous value: 2015-05-01"><div class="rowcollapse">09/15</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">2</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 255, 0); border-right-color: red;" title="Apr 2011 - Sep 2015">&nbsp;</td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=117570" target="_top">1298492</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01298492" target="_top" onclick="INC_ViewCount(117570)"><font id="ViewCount_117570"></font>OPERA II A Study To Monitor Long-Term Treatment With PF-00547659</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">210</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Canada, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">PF-00547659</div></td><td rowspan="1" class="title "><div class="rowcollapse">Pfizer </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title highlight" title="Previous value: 2016-08-01"><div class="rowcollapse">11/16</div></td><td rowspan="1" class="title "><div class="rowcollapse">2</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 255, 0); border-right-color: red;" title="Jul 2011 - Nov 2016">&nbsp;</td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=142203" target="_top">1620255</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01620255" target="_top" onclick="INC_ViewCount(142203)"><font id="ViewCount_142203"></font>TURANDOT A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">300</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">RoW</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">PF-00547659 SC Injection</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Pfizer </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Not yet recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">01/17</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">2</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 20px;" colspan="10" class="">&nbsp;</td><td colspan="29" style="width: 58px; background-color: rgb(255, 255, 0);" title="Nov 2012 - Jan 2017">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bHMPL004biHutch');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>HMPL-004</b> / <i>Hutchinson Medipharma</i></td></tr><tr style="display: none;" class="upms bHMPL004biHutch"><td><a href="http://larvoltrials.com/upm.php?search_id=4249" target="_top">4249</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=9084d8c6-81a8-42b3-aacc-6d084d6b7dc4&amp;ts=634796307325961250" target="_top">Global P3 studies (Ulcerative colitis)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Oct 2012 - Dec 2012 Global P3 studies (Ulcerative colitis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=9084d8c6-81a8-42b3-aacc-6d084d6b7dc4&amp;ts=634796307325961250" target="_top">&nbsp;</a></div></td><td style="width: 18px;" class="" colspan="9"><div title="Oct 2012 - Dec 2012 Global P3 studies (Ulcerative colitis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=9084d8c6-81a8-42b3-aacc-6d084d6b7dc4&amp;ts=634796307325961250" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Oct 2012 - Dec 2012 Global P3 studies (Ulcerative colitis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=9084d8c6-81a8-42b3-aacc-6d084d6b7dc4&amp;ts=634796307325961250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2012 - Dec 2012 Global P3 studies (Ulcerative colitis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=9084d8c6-81a8-42b3-aacc-6d084d6b7dc4&amp;ts=634796307325961250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2012 - Dec 2012 Global P3 studies (Ulcerative colitis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=9084d8c6-81a8-42b3-aacc-6d084d6b7dc4&amp;ts=634796307325961250" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Oct 2012 - Dec 2012 Global P3 studies (Ulcerative colitis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=9084d8c6-81a8-42b3-aacc-6d084d6b7dc4&amp;ts=634796307325961250" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bHMPL004biHutch"><td><a href="http://larvoltrials.com/upm.php?search_id=6052" target="_top">6052</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=4e77a4cc-ff41-4b50-9efb-8631b472947c&amp;ts=634712001629877301" target="_top">Product launch</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/17</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2017 - Dec 2017 Product launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=4e77a4cc-ff41-4b50-9efb-8631b472947c&amp;ts=634712001629877301" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2017 - Dec 2017 Product launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=4e77a4cc-ff41-4b50-9efb-8631b472947c&amp;ts=634712001629877301" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2017 - Dec 2017 Product launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=4e77a4cc-ff41-4b50-9efb-8631b472947c&amp;ts=634712001629877301" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2017 - Dec 2017 Product launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=4e77a4cc-ff41-4b50-9efb-8631b472947c&amp;ts=634712001629877301" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2017 - Dec 2017 Product launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=4e77a4cc-ff41-4b50-9efb-8631b472947c&amp;ts=634712001629877301" target="_top">&nbsp;</a></div></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=68613" target="_top">655733</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT00655733" target="_top" onclick="INC_ViewCount(68613)"><font id="ViewCount_68613"></font>Phase II Study of HMPL-004 in Subjects With Crohn's Disease</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">100</div></td><td rowspan="1" class="title "><div class="rowcollapse">US</div></td><td rowspan="1" class="title "><div class="rowcollapse">HMPL004, Placebo</div></td><td rowspan="1" class="title "><div class="rowcollapse">Hutchison Medipharma Limited </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">04/09</div></td><td rowspan="1" class="title "><div class="rowcollapse">2</div></td><td class="">&nbsp;</td><td colspan="3" style="width: 6px; background-color: rgb(255, 255, 0);" title="Apr 2006 - Apr 2009">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bVatelizumabbGB');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Vatelizumab</b> (GBR 500) / <i>Glenmark, Sanofi</i></td></tr><tr style="display: none;" class="upms bVatelizumabbGB"><td><a href="http://larvoltrials.com/upm.php?search_id=3982" target="_top">3982</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=44c2f134-4757-4ccb-bd97-c26bc16aba6f" target="_top">P2a trial initiation </a></div></td><td><div class="rowcollapse">Pending</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">09/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="P2a trial initiation "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=44c2f134-4757-4ccb-bd97-c26bc16aba6f" target="_top"><img src="hourglass.png" alt="Hourglass" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Sep 2012 P2a trial initiation "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=44c2f134-4757-4ccb-bd97-c26bc16aba6f" target="_top">&nbsp;</a></div></td><td style="width: 12px;" class="" colspan="6"><div title="Jul 2012 - Sep 2012 P2a trial initiation "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=44c2f134-4757-4ccb-bd97-c26bc16aba6f" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Jul 2012 - Sep 2012 P2a trial initiation "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=44c2f134-4757-4ccb-bd97-c26bc16aba6f" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Sep 2012 P2a trial initiation "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=44c2f134-4757-4ccb-bd97-c26bc16aba6f" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2012 - Sep 2012 P2a trial initiation "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=44c2f134-4757-4ccb-bd97-c26bc16aba6f" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2012 - Sep 2012 P2a trial initiation "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=44c2f134-4757-4ccb-bd97-c26bc16aba6f" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Sep 2012 P2a trial initiation "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=44c2f134-4757-4ccb-bd97-c26bc16aba6f" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bVatelizumabbGB"><td><a href="http://larvoltrials.com/upm.php?search_id=4928" target="_top">4928</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5a4300f0-d34c-4dd8-9079-1d64021707d1" target="_top">Data (MS)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">09/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Apr 2013 - Sep 2013 Data (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5a4300f0-d34c-4dd8-9079-1d64021707d1" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2013 - Sep 2013 Data (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5a4300f0-d34c-4dd8-9079-1d64021707d1" target="_top">&nbsp;</a></div></td><td style="width: 6px;" class="" colspan="3"><div title="Apr 2013 - Sep 2013 Data (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5a4300f0-d34c-4dd8-9079-1d64021707d1" target="_top">&nbsp;</a></div></td><td style="width: 12px; background-color: rgb(153, 102, 255);" colspan="6"><div title="Apr 2013 - Sep 2013 Data (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5a4300f0-d34c-4dd8-9079-1d64021707d1" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Apr 2013 - Sep 2013 Data (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5a4300f0-d34c-4dd8-9079-1d64021707d1" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Apr 2013 - Sep 2013 Data (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5a4300f0-d34c-4dd8-9079-1d64021707d1" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Apr 2013 - Sep 2013 Data (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5a4300f0-d34c-4dd8-9079-1d64021707d1" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bVatelizumabbGB"><td><a href="http://larvoltrials.com/upm.php?search_id=3472" target="_top">3472</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5df65960-7f9a-4a7f-b59f-521d83fb8e15" target="_top">Market Launch, MS</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/17</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2017 - Dec 2017 Market Launch, MS"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5df65960-7f9a-4a7f-b59f-521d83fb8e15" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2017 - Dec 2017 Market Launch, MS"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5df65960-7f9a-4a7f-b59f-521d83fb8e15" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2017 - Dec 2017 Market Launch, MS"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5df65960-7f9a-4a7f-b59f-521d83fb8e15" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2017 - Dec 2017 Market Launch, MS"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5df65960-7f9a-4a7f-b59f-521d83fb8e15" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2017 - Dec 2017 Market Launch, MS"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=5df65960-7f9a-4a7f-b59f-521d83fb8e15" target="_top">&nbsp;</a></div></td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=145144" target="_top">1659138</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01659138" target="_top" onclick="INC_ViewCount(145144)"><font id="ViewCount_145144"><span class="viewcount" title="Total views">2&nbsp;</span>&nbsp;</font>FUSCIA Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">84</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">SAR339658, Placebo</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Sanofi-Aventis </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">09/13</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">2</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 14px;" colspan="7" class="">&nbsp;</td><td style="width: 28px; background-color: rgb(255, 255, 0);" colspan="14" title="Aug 2012 - Sep 2013">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bbrodalumabbAMG');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>brodalumab</b> (AMG 827) / <i>AstraZeneca, Amgen, Kyowa Hakko Kirin</i></td></tr><tr style="display: none;" class="upms bbrodalumabbAMG"><td><a href="http://larvoltrials.com/upm.php?search_id=936" target="_top">936</a></td><td colspan="5" class=" highlight" title="Previous value: P3 study initiation (psoriasis)"><div class="rowcollapse"><a style="color: rgb(255, 0, 0);" href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3465c54e-28bf-469b-911f-d76e567cc946&amp;ts=634852869832551250" target="_top">Initiation of P3 study (psoriasis)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">12/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Dec 2012 - Dec 2012 Initiation of P3 study (psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3465c54e-28bf-469b-911f-d76e567cc946&amp;ts=634852869832551250" target="_top">&nbsp;</a></div></td><td style="width: 22px;" class="" colspan="11"><div title="Dec 2012 - Dec 2012 Initiation of P3 study (psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3465c54e-28bf-469b-911f-d76e567cc946&amp;ts=634852869832551250" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Dec 2012 - Dec 2012 Initiation of P3 study (psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3465c54e-28bf-469b-911f-d76e567cc946&amp;ts=634852869832551250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2012 - Dec 2012 Initiation of P3 study (psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3465c54e-28bf-469b-911f-d76e567cc946&amp;ts=634852869832551250" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2012 - Dec 2012 Initiation of P3 study (psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3465c54e-28bf-469b-911f-d76e567cc946&amp;ts=634852869832551250" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Dec 2012 - Dec 2012 Initiation of P3 study (psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3465c54e-28bf-469b-911f-d76e567cc946&amp;ts=634852869832551250" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bbrodalumabbAMG"><td><a href="http://larvoltrials.com/upm.php?search_id=935" target="_top">935</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=220f17d3-e22b-4472-9176-a9ec6269a67c" target="_top">Moderate to Severe Psoriasis P3 trial result </a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">12/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Dec 2013 Moderate to Severe Psoriasis P3 trial result "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=220f17d3-e22b-4472-9176-a9ec6269a67c" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2013 - Dec 2013 Moderate to Severe Psoriasis P3 trial result "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=220f17d3-e22b-4472-9176-a9ec6269a67c" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2013 - Dec 2013 Moderate to Severe Psoriasis P3 trial result "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=220f17d3-e22b-4472-9176-a9ec6269a67c" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2013 - Dec 2013 Moderate to Severe Psoriasis P3 trial result "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=220f17d3-e22b-4472-9176-a9ec6269a67c" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Dec 2013 Moderate to Severe Psoriasis P3 trial result "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=220f17d3-e22b-4472-9176-a9ec6269a67c" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bbrodalumabbAMG"><td><a href="http://larvoltrials.com/upm.php?search_id=5854" target="_top">5854</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ebb2be3c-9db1-43c3-ba75-6d7c9d1eea52&amp;ts=634699086017750000" target="_top">Launch (Psoriasis)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/15</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2015 - Dec 2015 Launch (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ebb2be3c-9db1-43c3-ba75-6d7c9d1eea52&amp;ts=634699086017750000" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2015 - Dec 2015 Launch (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ebb2be3c-9db1-43c3-ba75-6d7c9d1eea52&amp;ts=634699086017750000" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2015 - Dec 2015 Launch (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ebb2be3c-9db1-43c3-ba75-6d7c9d1eea52&amp;ts=634699086017750000" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2015 - Dec 2015 Launch (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ebb2be3c-9db1-43c3-ba75-6d7c9d1eea52&amp;ts=634699086017750000" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2015 - Dec 2015 Launch (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ebb2be3c-9db1-43c3-ba75-6d7c9d1eea52&amp;ts=634699086017750000" target="_top">&nbsp;</a></div></td></tr><tr><td colspan="53" class="norecord">No trials found</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bsecukinumabbAI');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>secukinumab</b> (AIN 457A) / <i>Novartis</i></td></tr><tr style="display: none;" class="upms bsecukinumabbAI"><td><a href="http://larvoltrials.com/upm.php?search_id=3361" target="_top">3361</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=13e14dec-877d-4632-8c26-bbf5206011d5" target="_top">P3 trial initiation in RA</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">09/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="P3 trial initiation in RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=3f5025ad-8c89-4b21-bfc0-cc55ed15cfb2&amp;ts=634598455760444130" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Sep 2011 - Sep 2011 P3 trial initiation in RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=13e14dec-877d-4632-8c26-bbf5206011d5" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Sep 2011 - Sep 2011 P3 trial initiation in RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=13e14dec-877d-4632-8c26-bbf5206011d5" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Sep 2011 - Sep 2011 P3 trial initiation in RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=13e14dec-877d-4632-8c26-bbf5206011d5" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Sep 2011 - Sep 2011 P3 trial initiation in RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=13e14dec-877d-4632-8c26-bbf5206011d5" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Sep 2011 - Sep 2011 P3 trial initiation in RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=13e14dec-877d-4632-8c26-bbf5206011d5" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bsecukinumabbAI"><td><a href="http://larvoltrials.com/upm.php?search_id=4244" target="_top">4244</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml" target="_top">Filing for noninfectious uveitis </a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Dec 2013 Filing for noninfectious uveitis "><a href="http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2013 - Dec 2013 Filing for noninfectious uveitis "><a href="http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2013 - Dec 2013 Filing for noninfectious uveitis "><a href="http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2013 - Dec 2013 Filing for noninfectious uveitis "><a href="http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Dec 2013 Filing for noninfectious uveitis "><a href="http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bsecukinumabbAI"><td><a href="http://larvoltrials.com/upm.php?search_id=6548" target="_top">6548</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=9b7e7c46-d03e-44eb-9bc8-17c15c5fe5c8" target="_top">Filing (Psoriasis)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jul 2013 - Dec 2013 Filing (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=9b7e7c46-d03e-44eb-9bc8-17c15c5fe5c8" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2013 - Dec 2013 Filing (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=9b7e7c46-d03e-44eb-9bc8-17c15c5fe5c8" target="_top">&nbsp;</a></div></td><td style="width: 12px;" class="" colspan="6"><div title="Jul 2013 - Dec 2013 Filing (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=9b7e7c46-d03e-44eb-9bc8-17c15c5fe5c8" target="_top">&nbsp;</a></div></td><td style="width: 12px; background-color: rgb(153, 102, 255);" colspan="6"><div title="Jul 2013 - Dec 2013 Filing (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=9b7e7c46-d03e-44eb-9bc8-17c15c5fe5c8" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2013 - Dec 2013 Filing (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=9b7e7c46-d03e-44eb-9bc8-17c15c5fe5c8" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2013 - Dec 2013 Filing (Psoriasis)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=9b7e7c46-d03e-44eb-9bc8-17c15c5fe5c8" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bsecukinumabbAI"><td><a href="http://larvoltrials.com/upm.php?search_id=933" target="_top">933</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b69b3e72-108d-4b5a-9653-3a2ea20ff69d" target="_top">Filing (RA, AS, PsA)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 Filing (RA, AS, PsA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b69b3e72-108d-4b5a-9653-3a2ea20ff69d" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2014 - Dec 2014 Filing (RA, AS, PsA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b69b3e72-108d-4b5a-9653-3a2ea20ff69d" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2014 - Dec 2014 Filing (RA, AS, PsA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b69b3e72-108d-4b5a-9653-3a2ea20ff69d" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2014 - Dec 2014 Filing (RA, AS, PsA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b69b3e72-108d-4b5a-9653-3a2ea20ff69d" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 Filing (RA, AS, PsA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b69b3e72-108d-4b5a-9653-3a2ea20ff69d" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bsecukinumabbAI"><td><a href="http://larvoltrials.com/upm.php?search_id=1982" target="_top">1982</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">US launch (RA)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 US launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2014 - Dec 2014 US launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2014 - Dec 2014 US launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2014 - Dec 2014 US launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 US launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bsecukinumabbAI"><td><a href="http://larvoltrials.com/upm.php?search_id=934" target="_top">934</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">US launch (psoriasis, PsA)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/15</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2015 US launch (psoriasis, PsA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2014 - Dec 2015 US launch (psoriasis, PsA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2014 - Dec 2015 US launch (psoriasis, PsA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">&nbsp;</a></div></td><td colspan="15" style="width: 30px; background-color: rgb(153, 102, 255);"><div title="Jan 2014 - Dec 2015 US launch (psoriasis, PsA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ce44dc12-c378-4e6a-85b1-7be9fa41211f" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bsecukinumabbAI"><td><a href="http://larvoltrials.com/upm.php?search_id=4814" target="_top">4814</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b6385fae-5966-4553-8296-8a9f0312981c" target="_top">Filing (MS)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/16</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2016 - Dec 2016 Filing (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b6385fae-5966-4553-8296-8a9f0312981c" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2016 - Dec 2016 Filing (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b6385fae-5966-4553-8296-8a9f0312981c" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2016 - Dec 2016 Filing (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b6385fae-5966-4553-8296-8a9f0312981c" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2016 - Dec 2016 Filing (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b6385fae-5966-4553-8296-8a9f0312981c" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2016 - Dec 2016 Filing (MS)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=b6385fae-5966-4553-8296-8a9f0312981c" target="_top">&nbsp;</a></div></td></tr><tr><td colspan="53" class="norecord">No trials found</td></tr><tr><td colspan="53" class="sectiontitles"><b>AMG 181</b> / <i>AstraZeneca, Amgen</i></td></tr><tr class="newtrial"><td class="title" title="New record"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=148051" target="_top">1694485</a></div></td><td rowspan="1" class="title highlight" title="Previous value: A Multiple Dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis"><div class="rowcollapse"><a style="color: rgb(255, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01694485" target="_top" onclick="INC_ViewCount(148051)"><font id="ViewCount_148051"><span class="viewcount" title="Total views">3&nbsp;</span>&nbsp;</font>A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis</a></div></td><td rowspan="1" class="title" title="New record" nowrap="nowrap"><div class="rowcollapse">315</div></td><td rowspan="1" class="title" title="New record"><div class="rowcollapse">US, Europe</div></td><td rowspan="1" class="title" title="New record"><div class="rowcollapse">AMG 181, Placebo</div></td><td rowspan="1" class="title" title="New record"><div class="rowcollapse">Amgen </div></td><td rowspan="1" class="title" title="New record"><div class="rowcollapse">Not yet recruiting</div></td><td rowspan="1" class="title" title="New record"><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="title" title="New record"><div class="rowcollapse">01/18</div></td><td rowspan="1" class="title" title="New record"><div class="rowcollapse">2</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 18px;" colspan="9" class="">&nbsp;</td><td colspan="30" style="width: 60px; background-color: rgb(255, 255, 0);" title="Oct 2012 - Jan 2018">&nbsp;</td></tr><tr class="newtrial"><td class="alttitle" title="New record"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=148198" target="_top">1696396</a></div></td><td rowspan="1" class="alttitle" title="New record"><div class="rowcollapse"><a style="color: rgb(255, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01696396" target="_top" onclick="INC_ViewCount(148198)"><font id="ViewCount_148198"><span class="viewcount" title="Total views">1&nbsp;</span>&nbsp;</font>AMG 181 in Subjects With Moderate to Severe Crohn's Disease</a></div></td><td rowspan="1" class="alttitle" title="New record" nowrap="nowrap"><div class="rowcollapse">252</div></td><td rowspan="1" class="alttitle" title="New record"><div class="rowcollapse">RoW</div></td><td rowspan="1" class="alttitle" title="New record"><div class="rowcollapse">AMG 181, Placebo</div></td><td rowspan="1" class="alttitle" title="New record"><div class="rowcollapse">Amgen </div></td><td rowspan="1" class="alttitle" title="New record"><div class="rowcollapse">Not yet recruiting</div></td><td rowspan="1" class="alttitle" title="New record"><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="alttitle" title="New record"><div class="rowcollapse">02/18</div></td><td rowspan="1" class="alttitle" title="New record"><div class="rowcollapse">2</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 20px;" colspan="10" class="">&nbsp;</td><td colspan="29" style="width: 58px; background-color: rgb(255, 255, 0);" title="Nov 2012 - Feb 2018">&nbsp;</td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=107336" target="_top">1164904</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01164904" target="_top" onclick="INC_ViewCount(107336)"><font id="ViewCount_107336"></font>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">76</div></td><td rowspan="1" class="title "><div class="rowcollapse">US</div></td><td rowspan="1" class="title "><div class="rowcollapse">Amg 181</div></td><td rowspan="1" class="title "><div class="rowcollapse">Amgen </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="title "><div class="rowcollapse">07/13</div></td><td rowspan="1" class="title "><div class="rowcollapse">1</div></td><td class="">&nbsp;</td><td style="width: 44px; background-color: rgb(153, 204, 0);" colspan="22" title="Jul 2010 - Jul 2013">&nbsp;</td><td style="width: 10px;" colspan="5">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=116923" target="_top">1290042</a></div></td><td rowspan="2" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01290042" target="_top" onclick="INC_ViewCount(116923)"><font id="ViewCount_116923"></font>Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.</a></div></td><td rowspan="2" class="alttitle " nowrap="nowrap"><div class="rowcollapse">64</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">US</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">AMG 181, Placebo for AMG 181</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Amgen </div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Ulcerative Colitis, Crohn's Disease</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">12/13</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">1</div></td><td class="">&nbsp;</td><td style="width: 54px; background-color: rgb(153, 204, 0);" colspan="27" title="Feb 2011 - Dec 2013">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td style="border-top: 0px none;" class="alttitle"><a style="color: gray;" href="http://larvoltrials.com/upm.php?search_id=5128" target="_top">5128</a></td><td style="text-align: center; vertical-align: middle;"><div data=""><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73bc39f5-b073-43d7-846a-24e94b070754&amp;ts=634652052344032102" target="_top"><img src="black-diamond.png" alt="Diamond" style="padding-top: 3px;" onclick="INC_ViewCount(116923)" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Feb 2012 - Feb 2012 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73bc39f5-b073-43d7-846a-24e94b070754&amp;ts=634652052344032102" target="_top">&nbsp;</a></div></td><td style="width: 2px;" class="" colspan="1"><div title="Feb 2012 - Feb 2012 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73bc39f5-b073-43d7-846a-24e94b070754&amp;ts=634652052344032102" target="_top">&nbsp;</a></div></td><td onclick="INC_ViewCount(116923)" style="width: 2px; background-color: rgb(153, 102, 255);"><div title="Feb 2012 - Feb 2012 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73bc39f5-b073-43d7-846a-24e94b070754&amp;ts=634652052344032102" target="_top">&nbsp;</a></div></td><td style="width: 20px;" colspan="10"><div title="Feb 2012 - Feb 2012 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73bc39f5-b073-43d7-846a-24e94b070754&amp;ts=634652052344032102" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Feb 2012 - Feb 2012 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73bc39f5-b073-43d7-846a-24e94b070754&amp;ts=634652052344032102" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Feb 2012 - Feb 2012 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73bc39f5-b073-43d7-846a-24e94b070754&amp;ts=634652052344032102" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Feb 2012 - Feb 2012 Data"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73bc39f5-b073-43d7-846a-24e94b070754&amp;ts=634652052344032102" target="_top">&nbsp;</a></div></td></tr><tr><td colspan="53" class="sectiontitles"><b>GSK1070806</b> / <i>GSK</i></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=97496" target="_top">1035645</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01035645" target="_top" onclick="INC_ViewCount(97496)"><font id="ViewCount_97496"></font>A18110040 First Time in Human Study of Intravenous Interleukin-18 Antibody</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">86</div></td><td rowspan="1" class="title "><div class="rowcollapse">Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">GSK1070806</div></td><td rowspan="1" class="title "><div class="rowcollapse">GlaxoSmithKline </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Bowel Disease, Inflammatory</div></td><td rowspan="1" class="title "><div class="rowcollapse">07/11</div></td><td rowspan="1" class="title "><div class="rowcollapse">1</div></td><td class="">&nbsp;</td><td colspan="3" style="width: 6px; background-color: rgb(153, 204, 0);" title="Jan 2010 - Jul 2011">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td colspan="53" class="sectiontitles"><b>baminercept</b> (BG9924, LTβR-Ig) / <i>Biogen Idec</i></td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=147779" target="_top">104UC201</a></div></td><td rowspan="1" class="alttitle manual" title="Manual curation. Original value: "><div class="rowcollapse"><a style="color: rgb(255, 119, 0);" href="http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2010-019558-42-BE" target="_top" onclick="INC_ViewCount(147779)"><font id="ViewCount_147779"><span class="viewcount" title="Total views">1&nbsp;</span>&nbsp;</font>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis</a></div></td><td rowspan="1" class="alttitle manual" title="Manual curation. Original value: " nowrap="nowrap"><div class="rowcollapse">100</div></td><td rowspan="1" class="alttitle manual" title="Manual curation."><div class="rowcollapse">RoW</div></td><td rowspan="1" class="alttitle manual" title="Manual curation. Original value: "><div class="rowcollapse">baminercept (BG9924, LTβR-Ig)</div></td><td rowspan="1" class="alttitle manual" title="Manual curation. Original value: "><div class="rowcollapse">Biogen Idec </div></td><td rowspan="1" class="alttitle manual" title="Manual curation. Original value: "><div class="rowcollapse">Active, not recruiting</div></td><td rowspan="1" class="alttitle manual" title="Manual curation. Original value: "><div class="rowcollapse">Moderate to Severe Ulcerative Colitis</div></td><td rowspan="1" class="alttitle manual" title="Manual curation. Original value: "><div class="rowcollapse">&nbsp;</div></td><td rowspan="1" class="alttitle manual" title="Manual curation. Original value: "><div class="rowcollapse">N/A</div></td><td class="">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'btofacitinibtas');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>tofacitinib, tasocitinib</b> (CP-690550) / <i>Pfizer</i></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4203" target="_top">4203</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=6e76ed7b-8596-43eb-8349-7b2a45c10f86" target="_top">Data release from P3 studies in RA in EULAR</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">05/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="Data release from P3 studies in RA in EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=6e76ed7b-8596-43eb-8349-7b2a45c10f86" target="_top"><img src="black-diamond.png" alt="Diamond" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="May 2011 - May 2011 Data release from P3 studies in RA in EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=6e76ed7b-8596-43eb-8349-7b2a45c10f86" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2011 - May 2011 Data release from P3 studies in RA in EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=6e76ed7b-8596-43eb-8349-7b2a45c10f86" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2011 - May 2011 Data release from P3 studies in RA in EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=6e76ed7b-8596-43eb-8349-7b2a45c10f86" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2011 - May 2011 Data release from P3 studies in RA in EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=6e76ed7b-8596-43eb-8349-7b2a45c10f86" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="May 2011 - May 2011 Data release from P3 studies in RA in EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=6e76ed7b-8596-43eb-8349-7b2a45c10f86" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4208" target="_top">4208</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">EU filing - RA</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">11/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="EU filing - RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ffeb13b8-5bc4-42fa-a192-1c3b72d7038c&amp;ts=634578934026158000" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Nov 2011 - Nov 2011 EU filing - RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Nov 2011 - Nov 2011 EU filing - RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Nov 2011 - Nov 2011 EU filing - RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Nov 2011 - Nov 2011 EU filing - RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Nov 2011 - Nov 2011 EU filing - RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4207" target="_top">4207</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">US filing - 5-and 10-milligram dose</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="US filing - 5-and 10-milligram dose"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=c4b1d8f2-545a-4455-b0fd-671e614888a2" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Dec 2011 - Dec 2011 US filing - 5-and 10-milligram dose"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2011 - Dec 2011 US filing - 5-and 10-milligram dose"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2011 - Dec 2011 US filing - 5-and 10-milligram dose"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2011 - Dec 2011 US filing - 5-and 10-milligram dose"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Dec 2011 - Dec 2011 US filing - 5-and 10-milligram dose"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4213" target="_top">4213</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">Filing in Japan, RA</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="Filing in Japan, RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=c4b1d8f2-545a-4455-b0fd-671e614888a2" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Dec 2011 - Dec 2011 Filing in Japan, RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2011 - Dec 2011 Filing in Japan, RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2011 - Dec 2011 Filing in Japan, RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2011 - Dec 2011 Filing in Japan, RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Dec 2011 - Dec 2011 Filing in Japan, RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c66a3633-a731-43ef-b7da-3cf2f66c0e93" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=5445" target="_top">5445</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73d9acc8-2dea-4944-b743-41ef2ad40de3&amp;ts=634711837079732135" target="_top">FDA advisory committee meeting (RA)</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">05/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="FDA advisory committee meeting (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e64a70d3-06f6-405e-9fcc-99697002eacf&amp;ts=634724109008051065" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="May 2012 - May 2012 FDA advisory committee meeting (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73d9acc8-2dea-4944-b743-41ef2ad40de3&amp;ts=634711837079732135" target="_top">&nbsp;</a></div></td><td style="width: 8px;" class="" colspan="4"><div title="May 2012 - May 2012 FDA advisory committee meeting (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73d9acc8-2dea-4944-b743-41ef2ad40de3&amp;ts=634711837079732135" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="May 2012 - May 2012 FDA advisory committee meeting (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73d9acc8-2dea-4944-b743-41ef2ad40de3&amp;ts=634711837079732135" target="_top">&nbsp;</a></div></td><td style="width: 14px;" colspan="7"><div title="May 2012 - May 2012 FDA advisory committee meeting (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73d9acc8-2dea-4944-b743-41ef2ad40de3&amp;ts=634711837079732135" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2012 - May 2012 FDA advisory committee meeting (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73d9acc8-2dea-4944-b743-41ef2ad40de3&amp;ts=634711837079732135" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2012 - May 2012 FDA advisory committee meeting (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73d9acc8-2dea-4944-b743-41ef2ad40de3&amp;ts=634711837079732135" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="May 2012 - May 2012 FDA advisory committee meeting (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=73d9acc8-2dea-4944-b743-41ef2ad40de3&amp;ts=634711837079732135" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=6582" target="_top">6582</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7bc187e9-0180-407a-a4a9-35e64f13a6a8&amp;ts=634724557599550515" target="_top">Cardiovascular safety data - EULAR 2012</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">06/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="Cardiovascular safety data - EULAR 2012"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eb9f7613-0f6a-46d8-9112-4568c27b831f&amp;ts=634749054353937500" target="_top"><img src="black-diamond.png" alt="Diamond" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Jun 2012 - Jun 2012 Cardiovascular safety data - EULAR 2012"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7bc187e9-0180-407a-a4a9-35e64f13a6a8&amp;ts=634724557599550515" target="_top">&nbsp;</a></div></td><td style="width: 10px;" class="" colspan="5"><div title="Jun 2012 - Jun 2012 Cardiovascular safety data - EULAR 2012"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7bc187e9-0180-407a-a4a9-35e64f13a6a8&amp;ts=634724557599550515" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Jun 2012 - Jun 2012 Cardiovascular safety data - EULAR 2012"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7bc187e9-0180-407a-a4a9-35e64f13a6a8&amp;ts=634724557599550515" target="_top">&nbsp;</a></div></td><td style="width: 12px;" colspan="6"><div title="Jun 2012 - Jun 2012 Cardiovascular safety data - EULAR 2012"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7bc187e9-0180-407a-a4a9-35e64f13a6a8&amp;ts=634724557599550515" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jun 2012 - Jun 2012 Cardiovascular safety data - EULAR 2012"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7bc187e9-0180-407a-a4a9-35e64f13a6a8&amp;ts=634724557599550515" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jun 2012 - Jun 2012 Cardiovascular safety data - EULAR 2012"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7bc187e9-0180-407a-a4a9-35e64f13a6a8&amp;ts=634724557599550515" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jun 2012 - Jun 2012 Cardiovascular safety data - EULAR 2012"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=7bc187e9-0180-407a-a4a9-35e64f13a6a8&amp;ts=634724557599550515" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4980" target="_top">4980</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">Additional sub-analysis data at EULAR (RA)</a></div></td><td><div class="rowcollapse">Pending</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">06/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="Additional sub-analysis data at EULAR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top"><img src="hourglass.png" alt="Hourglass" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Jun 2012 - Jun 2012 Additional sub-analysis data at EULAR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 10px;" class="" colspan="5"><div title="Jun 2012 - Jun 2012 Additional sub-analysis data at EULAR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Jun 2012 - Jun 2012 Additional sub-analysis data at EULAR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 12px;" colspan="6"><div title="Jun 2012 - Jun 2012 Additional sub-analysis data at EULAR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jun 2012 - Jun 2012 Additional sub-analysis data at EULAR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jun 2012 - Jun 2012 Additional sub-analysis data at EULAR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jun 2012 - Jun 2012 Additional sub-analysis data at EULAR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=7705" target="_top">7705</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ab70909b-0c69-475b-9d7f-a0d5107b5123&amp;ts=634809221454028750" target="_top">Additional data submission to FDA</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">08/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="Additional data submission to FDA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ab70909b-0c69-475b-9d7f-a0d5107b5123&amp;ts=634809221454028750" target="_top"><img src="black-checkmark.png" alt="Checkmark" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Aug 2012 - Aug 2012 Additional data submission to FDA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ab70909b-0c69-475b-9d7f-a0d5107b5123&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td style="width: 14px;" class="" colspan="7"><div title="Aug 2012 - Aug 2012 Additional data submission to FDA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ab70909b-0c69-475b-9d7f-a0d5107b5123&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Aug 2012 - Aug 2012 Additional data submission to FDA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ab70909b-0c69-475b-9d7f-a0d5107b5123&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td style="width: 8px;" colspan="4"><div title="Aug 2012 - Aug 2012 Additional data submission to FDA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ab70909b-0c69-475b-9d7f-a0d5107b5123&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Aug 2012 - Aug 2012 Additional data submission to FDA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ab70909b-0c69-475b-9d7f-a0d5107b5123&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Aug 2012 - Aug 2012 Additional data submission to FDA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ab70909b-0c69-475b-9d7f-a0d5107b5123&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Aug 2012 - Aug 2012 Additional data submission to FDA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ab70909b-0c69-475b-9d7f-a0d5107b5123&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4746" target="_top">4746</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=75887ab9-19a6-4026-b4c3-28908c2561d2&amp;ts=634627372191355824" target="_top">EU regulatory action for RA</a></div></td><td><div class="rowcollapse">Pending</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">09/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;"><div title="EU regulatory action for RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=75887ab9-19a6-4026-b4c3-28908c2561d2&amp;ts=634627372191355824" target="_top"><img src="hourglass.png" alt="Hourglass" border="0"></a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Sep 2012 EU regulatory action for RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=75887ab9-19a6-4026-b4c3-28908c2561d2&amp;ts=634627372191355824" target="_top">&nbsp;</a></div></td><td style="width: 12px;" class="" colspan="6"><div title="Jul 2012 - Sep 2012 EU regulatory action for RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=75887ab9-19a6-4026-b4c3-28908c2561d2&amp;ts=634627372191355824" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Jul 2012 - Sep 2012 EU regulatory action for RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=75887ab9-19a6-4026-b4c3-28908c2561d2&amp;ts=634627372191355824" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Sep 2012 EU regulatory action for RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=75887ab9-19a6-4026-b4c3-28908c2561d2&amp;ts=634627372191355824" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2012 - Sep 2012 EU regulatory action for RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=75887ab9-19a6-4026-b4c3-28908c2561d2&amp;ts=634627372191355824" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2012 - Sep 2012 EU regulatory action for RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=75887ab9-19a6-4026-b4c3-28908c2561d2&amp;ts=634627372191355824" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2012 - Sep 2012 EU regulatory action for RA"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=75887ab9-19a6-4026-b4c3-28908c2561d2&amp;ts=634627372191355824" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4981" target="_top">4981</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">Additional sub-analysis data at ACR (RA)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">11/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Nov 2012 - Nov 2012 Additional sub-analysis data at ACR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 20px;" class="" colspan="10"><div title="Nov 2012 - Nov 2012 Additional sub-analysis data at ACR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Nov 2012 - Nov 2012 Additional sub-analysis data at ACR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 2px;" colspan="1"><div title="Nov 2012 - Nov 2012 Additional sub-analysis data at ACR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Nov 2012 - Nov 2012 Additional sub-analysis data at ACR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Nov 2012 - Nov 2012 Additional sub-analysis data at ACR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Nov 2012 - Nov 2012 Additional sub-analysis data at ACR (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=432e2804-03e5-4569-ab3e-e0c0873107e7&amp;ts=634644525560181808" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4383" target="_top">4383</a></td><td colspan="5" class=" highlight" title="Previous value: FDA approval (RA)"><div class="rowcollapse"><a style="color: rgb(255, 0, 0);" href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=376006d1-bceb-46bb-bfd5-d1beb8e11ea0&amp;ts=634814412560063750" target="_top">PDUFA date (RA)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">11/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Nov 2012 - Nov 2012 PDUFA date (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=376006d1-bceb-46bb-bfd5-d1beb8e11ea0&amp;ts=634814412560063750" target="_top">&nbsp;</a></div></td><td style="width: 20px;" class="" colspan="10"><div title="Nov 2012 - Nov 2012 PDUFA date (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=376006d1-bceb-46bb-bfd5-d1beb8e11ea0&amp;ts=634814412560063750" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);"><div title="Nov 2012 - Nov 2012 PDUFA date (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=376006d1-bceb-46bb-bfd5-d1beb8e11ea0&amp;ts=634814412560063750" target="_top">&nbsp;</a></div></td><td style="width: 2px;" colspan="1"><div title="Nov 2012 - Nov 2012 PDUFA date (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=376006d1-bceb-46bb-bfd5-d1beb8e11ea0&amp;ts=634814412560063750" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Nov 2012 - Nov 2012 PDUFA date (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=376006d1-bceb-46bb-bfd5-d1beb8e11ea0&amp;ts=634814412560063750" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Nov 2012 - Nov 2012 PDUFA date (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=376006d1-bceb-46bb-bfd5-d1beb8e11ea0&amp;ts=634814412560063750" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Nov 2012 - Nov 2012 PDUFA date (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=376006d1-bceb-46bb-bfd5-d1beb8e11ea0&amp;ts=634814412560063750" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4455" target="_top">4455</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">P3 trial initiation, UC</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">12/12</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" class="" colspan="3"><div title="Jan 2012 - Dec 2012 P3 trial initiation, UC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2012 - Dec 2012 P3 trial initiation, UC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2012 - Dec 2012 P3 trial initiation, UC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2012 - Dec 2012 P3 trial initiation, UC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2012 - Dec 2012 P3 trial initiation, UC"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=8328" target="_top">8328</a></td><td colspan="5" class=" highlight" title="Previous value: Approval"><div class="rowcollapse"><a style="color: rgb(255, 0, 0);" href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a3eac4e0-6ad4-404a-9ee0-85d5dd8da435&amp;ts=634851952089203750" target="_top">Approval (RA)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">03/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Nov 2012 - Mar 2013 Approval (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a3eac4e0-6ad4-404a-9ee0-85d5dd8da435&amp;ts=634851952089203750" target="_top">&nbsp;</a></div></td><td style="width: 20px;" class="" colspan="10"><div title="Nov 2012 - Mar 2013 Approval (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a3eac4e0-6ad4-404a-9ee0-85d5dd8da435&amp;ts=634851952089203750" target="_top">&nbsp;</a></div></td><td style="width: 10px; background-color: rgb(153, 102, 255);" colspan="5"><div title="Nov 2012 - Mar 2013 Approval (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a3eac4e0-6ad4-404a-9ee0-85d5dd8da435&amp;ts=634851952089203750" target="_top">&nbsp;</a></div></td><td style="width: 18px;" colspan="9"><div title="Nov 2012 - Mar 2013 Approval (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a3eac4e0-6ad4-404a-9ee0-85d5dd8da435&amp;ts=634851952089203750" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Nov 2012 - Mar 2013 Approval (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a3eac4e0-6ad4-404a-9ee0-85d5dd8da435&amp;ts=634851952089203750" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Nov 2012 - Mar 2013 Approval (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a3eac4e0-6ad4-404a-9ee0-85d5dd8da435&amp;ts=634851952089203750" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=951" target="_top">951</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=41aac384-0bf8-4b31-be28-1acb2942aba6&amp;ts=634803518272147500" target="_top">Launch (RA)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">03/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Mar 2013 Launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=41aac384-0bf8-4b31-be28-1acb2942aba6&amp;ts=634803518272147500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2013 - Mar 2013 Launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=41aac384-0bf8-4b31-be28-1acb2942aba6&amp;ts=634803518272147500" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Jan 2013 - Mar 2013 Launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=41aac384-0bf8-4b31-be28-1acb2942aba6&amp;ts=634803518272147500" target="_top">&nbsp;</a></div></td><td style="width: 18px;" colspan="9"><div title="Jan 2013 - Mar 2013 Launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=41aac384-0bf8-4b31-be28-1acb2942aba6&amp;ts=634803518272147500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2013 - Mar 2013 Launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=41aac384-0bf8-4b31-be28-1acb2942aba6&amp;ts=634803518272147500" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Mar 2013 Launch (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=41aac384-0bf8-4b31-be28-1acb2942aba6&amp;ts=634803518272147500" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=7183" target="_top">7183</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ef002b8f-ef96-4ce7-a87c-23231ed738e6&amp;ts=634766880841535000" target="_top">NICE guidance (RA)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Pricing/Reimbursement Milestone</div></td><td class=""><div class="rowcollapse">09/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Sep 2013 - Sep 2013 NICE guidance (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ef002b8f-ef96-4ce7-a87c-23231ed738e6&amp;ts=634766880841535000" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Sep 2013 - Sep 2013 NICE guidance (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ef002b8f-ef96-4ce7-a87c-23231ed738e6&amp;ts=634766880841535000" target="_top">&nbsp;</a></div></td><td style="width: 16px;" class="" colspan="8"><div title="Sep 2013 - Sep 2013 NICE guidance (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ef002b8f-ef96-4ce7-a87c-23231ed738e6&amp;ts=634766880841535000" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Sep 2013 - Sep 2013 NICE guidance (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ef002b8f-ef96-4ce7-a87c-23231ed738e6&amp;ts=634766880841535000" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Sep 2013 - Sep 2013 NICE guidance (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ef002b8f-ef96-4ce7-a87c-23231ed738e6&amp;ts=634766880841535000" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Sep 2013 - Sep 2013 NICE guidance (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ef002b8f-ef96-4ce7-a87c-23231ed738e6&amp;ts=634766880841535000" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Sep 2013 - Sep 2013 NICE guidance (RA)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=ef002b8f-ef96-4ce7-a87c-23231ed738e6&amp;ts=634766880841535000" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4807" target="_top">4807</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e44f0ac6-2d5c-4919-9994-22b0cc01e714&amp;ts=634633794529781096" target="_top">Regulatory action in Japan</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" class="" colspan="3"><div title="Jan 2012 - Dec 2013 Regulatory action in Japan"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e44f0ac6-2d5c-4919-9994-22b0cc01e714&amp;ts=634633794529781096" target="_top">&nbsp;</a></div></td><td style="width: 46px; background-color: rgb(153, 102, 255);" colspan="23"><div title="Jan 2012 - Dec 2013 Regulatory action in Japan"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e44f0ac6-2d5c-4919-9994-22b0cc01e714&amp;ts=634633794529781096" target="_top">&nbsp;</a></div></td><td style="width: 2px;" colspan="1"><div title="Jan 2012 - Dec 2013 Regulatory action in Japan"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e44f0ac6-2d5c-4919-9994-22b0cc01e714&amp;ts=634633794529781096" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2012 - Dec 2013 Regulatory action in Japan"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e44f0ac6-2d5c-4919-9994-22b0cc01e714&amp;ts=634633794529781096" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2012 - Dec 2013 Regulatory action in Japan"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=e44f0ac6-2d5c-4919-9994-22b0cc01e714&amp;ts=634633794529781096" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=4209" target="_top">4209</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=0a978200-6404-420e-8005-7e3dcada26a9" target="_top">Launch for psoriasis in EU</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 Launch for psoriasis in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=0a978200-6404-420e-8005-7e3dcada26a9" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2014 - Dec 2014 Launch for psoriasis in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=0a978200-6404-420e-8005-7e3dcada26a9" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2014 - Dec 2014 Launch for psoriasis in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=0a978200-6404-420e-8005-7e3dcada26a9" target="_top">&nbsp;</a></div></td><td style="width: 24px; background-color: rgb(153, 102, 255);" colspan="12"><div title="Jan 2014 - Dec 2014 Launch for psoriasis in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=0a978200-6404-420e-8005-7e3dcada26a9" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Dec 2014 Launch for psoriasis in EU"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemId=0a978200-6404-420e-8005-7e3dcada26a9" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms btofacitinibtas"><td><a href="http://larvoltrials.com/upm.php?search_id=6470" target="_top">6470</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=20fa3149-485f-4b58-a94d-c78464305603&amp;ts=634718536845827507" target="_top">Post-marketing study</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">12/17</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Dec 2017 Post-marketing study"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=20fa3149-485f-4b58-a94d-c78464305603&amp;ts=634718536845827507" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2013 - Dec 2017 Post-marketing study"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=20fa3149-485f-4b58-a94d-c78464305603&amp;ts=634718536845827507" target="_top">&nbsp;</a></div></td><td colspan="27" style="width: 54px; background-color: rgb(153, 102, 255);"><div title="Jan 2013 - Dec 2017 Post-marketing study"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=20fa3149-485f-4b58-a94d-c78464305603&amp;ts=634718536845827507" target="_top">&nbsp;</a></div></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=130356" target="_top">1465763</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01465763" target="_top" onclick="INC_ViewCount(130356)"><font id="ViewCount_130356"></font>OCTAVE A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">545</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">CP-690,550, Placebo</div></td><td rowspan="1" class="title "><div class="rowcollapse">Pfizer </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="title "><div class="rowcollapse">12/13</div></td><td rowspan="1" class="title "><div class="rowcollapse">3</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 6px;" colspan="3" class="">&nbsp;</td><td style="width: 42px; background-color: rgb(255, 153, 0);" colspan="21" title="Apr 2012 - Dec 2013">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=129833" target="_top">1458951</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01458951" target="_top" onclick="INC_ViewCount(129833)"><font id="ViewCount_129833"></font>OCTAVE A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">545</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US, Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">CP-690,550, Placebo</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Pfizer </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">04/14</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">3</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 10px;" colspan="5" class="">&nbsp;</td><td style="width: 46px; background-color: rgb(255, 153, 0);" colspan="23" title="Jun 2012 - Apr 2014">&nbsp;</td><td style="width: 16px;" colspan="8">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=129804" target="_top">1458574</a></div></td><td rowspan="2" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01458574" target="_top" onclick="INC_ViewCount(129804)"><font id="ViewCount_129804"><span class="viewcount" title="Total views">1&nbsp;</span>&nbsp;</font>OCTAVE A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis</a></div></td><td rowspan="2" class="title " nowrap="nowrap"><div class="rowcollapse">654</div></td><td rowspan="2" class="title "><div class="rowcollapse">US, Europe</div></td><td rowspan="2" class="title "><div class="rowcollapse">Placebo, CP690,550</div></td><td rowspan="2" class="title "><div class="rowcollapse">Pfizer </div></td><td rowspan="2" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="2" class="title "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="2" class="title "><div class="rowcollapse">04/15</div></td><td rowspan="2" class="title "><div class="rowcollapse">3</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 12px;" colspan="6" class="">&nbsp;</td><td colspan="33" style="width: 66px; background-color: rgb(255, 153, 0);" title="Jul 2012 - Apr 2015">&nbsp;</td></tr><tr><td style="border-top: 0px none;" class="title"><a style="color: gray;" href="http://larvoltrials.com/upm.php?search_id=7704" target="_top">7704</a></td><td style="text-align: center; vertical-align: middle;"><div trial="" completion="" (uc)="">&nbsp;</div></td><td style="width: 6px;" colspan="3"><div title="Dec 2015 - Dec 2015 Trial completion (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a6b212d1-c2db-41e0-b89e-aa1ca7910cf0&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2015 - Dec 2015 Trial completion (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a6b212d1-c2db-41e0-b89e-aa1ca7910cf0&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Dec 2015 - Dec 2015 Trial completion (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a6b212d1-c2db-41e0-b89e-aa1ca7910cf0&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Dec 2015 - Dec 2015 Trial completion (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a6b212d1-c2db-41e0-b89e-aa1ca7910cf0&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td><td onclick="INC_ViewCount(129804)" colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Dec 2015 - Dec 2015 Trial completion (UC)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a6b212d1-c2db-41e0-b89e-aa1ca7910cf0&amp;ts=634809221454028750" target="_top">&nbsp;</a></div></td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=130727" target="_top">1470612</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01470612" target="_top" onclick="INC_ViewCount(130727)"><font id="ViewCount_130727"></font>OCTAVE Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">725</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US, Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">CP-690,550</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Pfizer </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Not yet recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Ulcerative Colitis</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">04/16</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">3</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 16px;" colspan="8" class="">&nbsp;</td><td colspan="31" style="width: 62px; background-color: rgb(255, 153, 0);" title="Sep 2012 - Apr 2016">&nbsp;</td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=124833" target="_top">1393626</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01393626" target="_top" onclick="INC_ViewCount(124833)"><font id="ViewCount_124833"></font>A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">275</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">Placebo, CP-690,550</div></td><td rowspan="1" class="title "><div class="rowcollapse">Pfizer </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">05/13</div></td><td rowspan="1" class="title "><div class="rowcollapse">2</div></td><td class="">&nbsp;</td><td style="width: 40px; background-color: rgb(255, 255, 0);" colspan="20" title="Oct 2011 - May 2013">&nbsp;</td><td style="width: 14px;" colspan="7">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=124854" target="_top">1393899</a></div></td><td rowspan="2" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01393899" target="_top" onclick="INC_ViewCount(124854)"><font id="ViewCount_124854"><span class="viewcount" title="Total views">1&nbsp;</span>&nbsp;</font>The Safety And Efficacy Of Maintenance Therapy With CP-690,550</a></div></td><td rowspan="2" class="alttitle " nowrap="nowrap"><div class="rowcollapse">90</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Placebo, CP-690,550</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Pfizer </div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">11/13</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">2</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 4px;" colspan="2" class="">&nbsp;</td><td style="width: 42px; background-color: rgb(255, 255, 0);" colspan="21" title="Mar 2012 - Nov 2013">&nbsp;</td><td style="width: 2px;" colspan="1">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td style="border-top: 0px none;" class="alttitle"><a style="color: gray;" href="http://larvoltrials.com/upm.php?search_id=4456" target="_top">4456</a></td><td style="text-align: center; vertical-align: middle;"><div p2="" trial="" initiation,="" cd=""><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=8830e4ea-469e-432a-85f9-01982a73b523&amp;ts=634718667239906232" target="_top"><img src="black-checkmark.png" alt="Checkmark" style="padding-top: 3px;" onclick="INC_ViewCount(124854)" border="0"></a></div></td><td style="width: 6px;" class="" colspan="3"><div title="Jan 2012 - Jan 2012 P2 trial initiation, CD"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td><td onclick="INC_ViewCount(124854)" style="width: 2px; background-color: rgb(153, 102, 255);"><div title="Jan 2012 - Jan 2012 P2 trial initiation, CD"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td><td style="width: 22px;" colspan="11"><div title="Jan 2012 - Jan 2012 P2 trial initiation, CD"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2012 - Jan 2012 P2 trial initiation, CD"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2012 - Jan 2012 P2 trial initiation, CD"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2012 - Jan 2012 P2 trial initiation, CD"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=c7fe12af-c5a2-426a-9b16-897874407c8f&amp;ts=634609668463091764" target="_top">&nbsp;</a></div></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=130726" target="_top">1470599</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01470599" target="_top" onclick="INC_ViewCount(130726)"><font id="ViewCount_130726"></font>A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">90</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">CP-690,550</div></td><td rowspan="1" class="title "><div class="rowcollapse">Pfizer </div></td><td rowspan="1" class="title "><div class="rowcollapse">Enrolling by invitation</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">10/14</div></td><td rowspan="1" class="title "><div class="rowcollapse">2</div></td><td>&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td><td style="width: 6px;" colspan="3" class="">&nbsp;</td><td style="width: 62px; background-color: rgb(255, 255, 0);" colspan="31" title="Apr 2012 - Oct 2014">&nbsp;</td><td style="width: 4px;" colspan="2">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bvercirnonbTraf');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>vercirnon</b> (Traficet-EN, CCX282-B, GSK1605786) / <i>GSK, ChemoCentryx</i></td></tr><tr style="display: none;" class="upms bvercirnonbTraf"><td><a href="http://larvoltrials.com/upm.php?search_id=5663" target="_top">5663</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">P3 SHIELD-4 trial completion</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">01/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Jan 2014 P3 SHIELD-4 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2014 - Jan 2014 P3 SHIELD-4 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2014 - Jan 2014 P3 SHIELD-4 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Jan 2014 - Jan 2014 P3 SHIELD-4 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 22px;" colspan="11"><div title="Jan 2014 - Jan 2014 P3 SHIELD-4 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2014 - Jan 2014 P3 SHIELD-4 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvercirnonbTraf"><td><a href="http://larvoltrials.com/upm.php?search_id=5661" target="_top">5661</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">P3 SHIELD-2 trial completion</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">07/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jul 2014 - Jul 2014 P3 SHIELD-2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2014 - Jul 2014 P3 SHIELD-2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2014 - Jul 2014 P3 SHIELD-2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 12px;" class="" colspan="6"><div title="Jul 2014 - Jul 2014 P3 SHIELD-2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 2px; background-color: rgb(153, 102, 255);" colspan="1"><div title="Jul 2014 - Jul 2014 P3 SHIELD-2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 10px;" colspan="5"><div title="Jul 2014 - Jul 2014 P3 SHIELD-2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jul 2014 - Jul 2014 P3 SHIELD-2 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvercirnonbTraf"><td><a href="http://larvoltrials.com/upm.php?search_id=5664" target="_top">5664</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">US filing</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Oct 2014 - Dec 2014 US filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2014 - Dec 2014 US filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2014 - Dec 2014 US filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 18px;" class="" colspan="9"><div title="Oct 2014 - Dec 2014 US filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Oct 2014 - Dec 2014 US filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Oct 2014 - Dec 2014 US filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvercirnonbTraf"><td><a href="http://larvoltrials.com/upm.php?search_id=5665" target="_top">5665</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">EU filing</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/14</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Oct 2014 - Dec 2014 EU filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2014 - Dec 2014 EU filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Oct 2014 - Dec 2014 EU filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 18px;" class="" colspan="9"><div title="Oct 2014 - Dec 2014 EU filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Oct 2014 - Dec 2014 EU filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Oct 2014 - Dec 2014 EU filing"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvercirnonbTraf"><td><a href="http://larvoltrials.com/upm.php?search_id=5662" target="_top">5662</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">P3 SHIELD-3 trial completion</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">07/15</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jul 2015 - Jul 2015 P3 SHIELD-3 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2015 - Jul 2015 P3 SHIELD-3 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jul 2015 - Jul 2015 P3 SHIELD-3 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jul 2015 - Jul 2015 P3 SHIELD-3 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jul 2015 - Jul 2015 P3 SHIELD-3 trial completion"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvercirnonbTraf"><td><a href="http://larvoltrials.com/upm.php?search_id=5666" target="_top">5666</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d24a8b5c-30ad-481f-a804-2c1fdb1f0b42&amp;ts=634687526528993705" target="_top">Regulatory approval</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/15</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2015 - Dec 2015 Regulatory approval"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d24a8b5c-30ad-481f-a804-2c1fdb1f0b42&amp;ts=634687526528993705" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2015 - Dec 2015 Regulatory approval"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d24a8b5c-30ad-481f-a804-2c1fdb1f0b42&amp;ts=634687526528993705" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2015 - Dec 2015 Regulatory approval"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d24a8b5c-30ad-481f-a804-2c1fdb1f0b42&amp;ts=634687526528993705" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2015 - Dec 2015 Regulatory approval"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d24a8b5c-30ad-481f-a804-2c1fdb1f0b42&amp;ts=634687526528993705" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2015 - Dec 2015 Regulatory approval"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=d24a8b5c-30ad-481f-a804-2c1fdb1f0b42&amp;ts=634687526528993705" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvercirnonbTraf"><td><a href="http://larvoltrials.com/upm.php?search_id=5668" target="_top">5668</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">Launch</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/15</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2015 - Dec 2015 Launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2015 - Dec 2015 Launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2015 - Dec 2015 Launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2015 - Dec 2015 Launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2015 - Dec 2015 Launch"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvercirnonbTraf"><td><a href="http://larvoltrials.com/upm.php?search_id=5667" target="_top">5667</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">Patent expiry</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Commercial Milestone</div></td><td class=""><div class="rowcollapse">12/25</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2024 - Dec 2025 Patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2024 - Dec 2025 Patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2024 - Dec 2025 Patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2024 - Dec 2025 Patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2024 - Dec 2025 Patent expiry"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=eca13a65-5252-4132-a82d-2417d6849b37&amp;ts=634687061397960057" target="_top">&nbsp;</a></div></td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=115977" target="_top">1277666</a></div></td><td rowspan="2" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01277666" target="_top" onclick="INC_ViewCount(115977)"><font id="ViewCount_115977"></font>SHIELD-1 A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease</a></div></td><td rowspan="2" class="alttitle " nowrap="nowrap"><div class="rowcollapse">600</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">GSK1605786A, Placebo</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">GlaxoSmithKline </div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">08/13</div></td><td rowspan="2" class="alttitle "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td style="width: 46px; background-color: rgb(255, 153, 0);" colspan="23" title="Dec 2010 - Aug 2013">&nbsp;</td><td style="width: 8px;" colspan="4">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td style="border-top: 0px none;" class="alttitle"><a style="color: gray;" href="http://larvoltrials.com/upm.php?search_id=6805" target="_top">6805</a></td><td style="text-align: center; vertical-align: middle;"><div p3="" data="" (shield-1)="">&nbsp;</div></td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Jun 2013 P3 data (SHIELD-1)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=044a8b94-6b91-4f1b-8d7c-351af7b4ad84&amp;ts=634833635031667500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2013 - Jun 2013 P3 data (SHIELD-1)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=044a8b94-6b91-4f1b-8d7c-351af7b4ad84&amp;ts=634833635031667500" target="_top">&nbsp;</a></div></td><td onclick="INC_ViewCount(115977)" style="width: 12px; background-color: rgb(153, 102, 255);" colspan="6"><div title="Jan 2013 - Jun 2013 P3 data (SHIELD-1)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=044a8b94-6b91-4f1b-8d7c-351af7b4ad84&amp;ts=634833635031667500" target="_top">&nbsp;</a></div></td><td style="width: 12px;" colspan="6"><div title="Jan 2013 - Jun 2013 P3 data (SHIELD-1)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=044a8b94-6b91-4f1b-8d7c-351af7b4ad84&amp;ts=634833635031667500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2013 - Jun 2013 P3 data (SHIELD-1)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=044a8b94-6b91-4f1b-8d7c-351af7b4ad84&amp;ts=634833635031667500" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Jun 2013 P3 data (SHIELD-1)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=044a8b94-6b91-4f1b-8d7c-351af7b4ad84&amp;ts=634833635031667500" target="_top">&nbsp;</a></div></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=135771" target="_top">1536418</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01536418" target="_top" onclick="INC_ViewCount(135771)"><font id="ViewCount_135771"></font>SHIELD-4 An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">900</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">GSK1605786A</div></td><td rowspan="1" class="title "><div class="rowcollapse">GlaxoSmithKline </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">01/14</div></td><td rowspan="1" class="title "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td style="width: 56px; background-color: rgb(255, 153, 0);" colspan="28" title="Nov 2011 - Jan 2014">&nbsp;</td><td style="width: 22px;" colspan="11">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=118980" target="_top">NCT01316939
2010-022383-12</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01316939" target="_top" onclick="INC_ViewCount(118980)"><font id="ViewCount_118980"></font>SHIELD-2 GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">756</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">GSK1605786A, Placebo</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">GlaxoSmithKline </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">04/15</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 153, 0);" title="May 2011 - Apr 2015">&nbsp;</td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=119136" target="_top">NCT01318993
2010-022384-35</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01318993" target="_top" onclick="INC_ViewCount(119136)"><font id="ViewCount_119136"></font>SHIELD-3 Open-Label Extension Study of GSK1605786A</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">800</div></td><td rowspan="1" class="title "><div class="rowcollapse">US, Canada, Japan, Europe</div></td><td rowspan="1" class="title "><div class="rowcollapse">GSK1605786A</div></td><td rowspan="1" class="title "><div class="rowcollapse">GlaxoSmithKline </div></td><td rowspan="1" class="title "><div class="rowcollapse">Recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">07/15</div></td><td rowspan="1" class="title "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td colspan="42" style="width: 84px; background-color: rgb(255, 153, 0);" title="Apr 2011 - Jul 2015">&nbsp;</td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=145103" target="_top">1658605</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT01658605" target="_top" onclick="INC_ViewCount(145103)"><font id="ViewCount_145103"></font>A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">45</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">RoW</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">GSK1605786, Placebo</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">GlaxoSmithKline </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Not yet recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Colitis, Ulcerative</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">12/14</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">2</div></td><td>&nbsp;</td><td colspan="3" style="width: 6px;">&nbsp;</td><td colspan="12" style="width: 24px;" class="">&nbsp;</td><td style="width: 48px; background-color: rgb(255, 255, 0);" colspan="24" title="Jan 2013 - Dec 2014">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td colspan="53" class="sectiontitles"><b>tetomilast</b> (OPC-6535) / <i>Otsuka</i></td></tr><tr><td class="title"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=93971" target="_top">989573</a></div></td><td rowspan="1" class="title "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT00989573" target="_top" onclick="INC_ViewCount(93971)"><font id="ViewCount_93971"></font>A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease</a></div></td><td rowspan="1" class="title " nowrap="nowrap"><div class="rowcollapse">180</div></td><td rowspan="1" class="title "><div class="rowcollapse">Japan</div></td><td rowspan="1" class="title "><div class="rowcollapse">Placebo, OPC-6535</div></td><td rowspan="1" class="title "><div class="rowcollapse">Otsuka Pharmaceutical Co., Ltd. </div></td><td rowspan="1" class="title "><div class="rowcollapse">Active, not recruiting</div></td><td rowspan="1" class="title "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="title "><div class="rowcollapse">12/12</div></td><td rowspan="1" class="title "><div class="rowcollapse">2/3</div></td><td class="">&nbsp;</td><td style="width: 30px; background-color: rgb(255, 153, 0);" colspan="15" title="Oct 2009 - Dec 2012">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr><td colspan="53" class="sectiontitles"><b>alicaforsen</b> (ISIS-2302) / <i>Isis, Atlantic Healthcare</i></td></tr><tr><td class="alttitle"><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://larvoltrials.com/edit_trials.php?larvol_id=23121" target="_top">48295</a></div></td><td rowspan="1" class="alttitle "><div class="rowcollapse"><a style="color: rgb(0, 0, 0);" href="http://clinicaltrials.gov/ct2/show/NCT00048295" target="_top" onclick="INC_ViewCount(23121)"><font id="ViewCount_23121"></font>Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease</a></div></td><td rowspan="1" class="alttitle " nowrap="nowrap"><div class="rowcollapse">150</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Europe</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Alicaforsen</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Isis Pharmaceuticals </div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Active, not recruiting</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">Crohn's Disease</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">06/05</div></td><td rowspan="1" class="alttitle "><div class="rowcollapse">3</div></td><td class="">&nbsp;</td><td colspan="3" style="width: 6px; background-color: rgb(255, 153, 0);" title="May 2002 - Jun 2005">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 24px;" colspan="12">&nbsp;</td><td style="width: 6px;" colspan="3">&nbsp;</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bsotrastaurinbN');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>sotrastaurin</b> (NVP AEB071) / <i>Novartis</i></td></tr><tr style="display: none;" class="upms bsotrastaurinbN"><td><a href="http://larvoltrials.com/upm.php?search_id=952" target="_top">952</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a0d98ae2-1fd7-4c3a-baf2-b17574e57802&amp;ts=634632421129526195" target="_top">Regulatory filing for psoriasis</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Regulatory Milestone</div></td><td class=""><div class="rowcollapse">12/16</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2016 - Dec 2016 Regulatory filing for psoriasis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a0d98ae2-1fd7-4c3a-baf2-b17574e57802&amp;ts=634632421129526195" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2016 - Dec 2016 Regulatory filing for psoriasis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a0d98ae2-1fd7-4c3a-baf2-b17574e57802&amp;ts=634632421129526195" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2016 - Dec 2016 Regulatory filing for psoriasis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a0d98ae2-1fd7-4c3a-baf2-b17574e57802&amp;ts=634632421129526195" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2016 - Dec 2016 Regulatory filing for psoriasis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a0d98ae2-1fd7-4c3a-baf2-b17574e57802&amp;ts=634632421129526195" target="_top">&nbsp;</a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2016 - Dec 2016 Regulatory filing for psoriasis"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=a0d98ae2-1fd7-4c3a-baf2-b17574e57802&amp;ts=634632421129526195" target="_top">&nbsp;</a></div></td></tr><tr><td colspan="53" class="norecord">No trials found</td></tr><tr class="trialtitles"><td colspan="53" class="upmpointer sectiontitles" style="background: url('up.png') no-repeat scroll left center transparent;" onclick="sh(this,'bvidofludimusb4');">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>vidofludimus</b> (4SC101, SC12267) / <i>4SC</i></td></tr><tr style="display: none;" class="upms bvidofludimusb4"><td><a href="http://larvoltrials.com/upm.php?search_id=4238" target="_top">4238</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=864d7b05-8f4e-4c24-b5ce-ec69e2c8d443" target="_top">Pre-clinical data on SLE at EULAR</a></div></td><td><div class="rowcollapse">Occurred</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">05/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="Pre-clinical data on SLE at EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=864d7b05-8f4e-4c24-b5ce-ec69e2c8d443" target="_top"><img src="black-diamond.png" alt="Diamond" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="May 2011 - May 2011 Pre-clinical data on SLE at EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=864d7b05-8f4e-4c24-b5ce-ec69e2c8d443" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2011 - May 2011 Pre-clinical data on SLE at EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=864d7b05-8f4e-4c24-b5ce-ec69e2c8d443" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2011 - May 2011 Pre-clinical data on SLE at EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=864d7b05-8f4e-4c24-b5ce-ec69e2c8d443" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="May 2011 - May 2011 Pre-clinical data on SLE at EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=864d7b05-8f4e-4c24-b5ce-ec69e2c8d443" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="May 2011 - May 2011 Pre-clinical data on SLE at EULAR"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=864d7b05-8f4e-4c24-b5ce-ec69e2c8d443" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvidofludimusb4"><td><a href="http://larvoltrials.com/upm.php?search_id=4239" target="_top">4239</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=05971810-5635-4cb5-bc63-87d5c2d6903d" target="_top">PoC data in RA </a></div></td><td><div class="rowcollapse">Pending</div></td><td class=""><div class="rowcollapse">Clinical Data Milestone</div></td><td class=""><div class="rowcollapse">12/11</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;" class=""><div title="PoC data in RA "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=05971810-5635-4cb5-bc63-87d5c2d6903d" target="_top"><img src="hourglass.png" alt="Hourglass" border="0"></a></div></td><td colspan="3" style="width: 6px; background-color: rgb(153, 102, 255);"><div title="Jan 2011 - Dec 2011 PoC data in RA "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=05971810-5635-4cb5-bc63-87d5c2d6903d" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2011 - Dec 2011 PoC data in RA "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=05971810-5635-4cb5-bc63-87d5c2d6903d" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2011 - Dec 2011 PoC data in RA "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=05971810-5635-4cb5-bc63-87d5c2d6903d" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2011 - Dec 2011 PoC data in RA "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=05971810-5635-4cb5-bc63-87d5c2d6903d" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2011 - Dec 2011 PoC data in RA "><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=05971810-5635-4cb5-bc63-87d5c2d6903d" target="_top">&nbsp;</a></div></td></tr><tr style="display: none;" class="upms bvidofludimusb4"><td><a href="http://larvoltrials.com/upm.php?search_id=5670" target="_top">5670</a></td><td colspan="5" class=""><div class="rowcollapse"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=795c5524-a085-4693-9dac-4369864cd4f6&amp;ts=634802291008867500" target="_top">P2b trial initiation (IBD)</a></div></td><td><div class="rowcollapse">Upcoming</div></td><td class=""><div class="rowcollapse">Clinical Milestone</div></td><td class=""><div class="rowcollapse">03/13</div></td><td><div class="rowcollapse">&nbsp;</div></td><td style="text-align: center; vertical-align: middle;">&nbsp;</td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Mar 2013 P2b trial initiation (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=795c5524-a085-4693-9dac-4369864cd4f6&amp;ts=634802291008867500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" class="" colspan="12"><div title="Jan 2013 - Mar 2013 P2b trial initiation (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=795c5524-a085-4693-9dac-4369864cd4f6&amp;ts=634802291008867500" target="_top">&nbsp;</a></div></td><td style="width: 6px; background-color: rgb(153, 102, 255);" colspan="3"><div title="Jan 2013 - Mar 2013 P2b trial initiation (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=795c5524-a085-4693-9dac-4369864cd4f6&amp;ts=634802291008867500" target="_top">&nbsp;</a></div></td><td style="width: 18px;" colspan="9"><div title="Jan 2013 - Mar 2013 P2b trial initiation (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=795c5524-a085-4693-9dac-4369864cd4f6&amp;ts=634802291008867500" target="_top">&nbsp;</a></div></td><td style="width: 24px;" colspan="12"><div title="Jan 2013 - Mar 2013 P2b trial initiation (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=795c5524-a085-4693-9dac-4369864cd4f6&amp;ts=634802291008867500" target="_top">&nbsp;</a></div></td><td style="width: 6px;" colspan="3"><div title="Jan 2013 - Mar 2013 P2b trial initiation (IBD)"><a href="http://www.larvolinsight.com/NewsItem/Default.aspx?NewsItemID=795c5524-a085-4693-9dac-4369864cd4f6&amp;ts=634802291008867500" target="_top">&nbsp;</a></div></td></tr><tr><td colspan="53" class="norecord">No trials found</td></tr></tbody></table><input name="cd" value="S7QysqoutjK0UkpUss60MjG2LgaKKGXmgXhmhta1AA%3D%3D" type="hidden"><input name="minenroll" id="minenroll" value="0" type="hidden"><input name="maxenroll" id="maxenroll" value="2200" type="hidden"></form><br><div id="dropmenu" class="dropmenudiv" style="width: 310px;"><div style="height: 180px; padding: 6px;"><div class="downldbox"><div class="newtext">Download Options</div><form id="frmDOptions" name="frmDOptions" method="post" target="_self" action="http://www.larvoltrials.com/intermediary.php?p=4108,2082,3514,2976,4163,3191,4365,1580,255,2778,3615,1887,4101,462,3509,4473,3060,1599,2399,205,2183,1159,2034,3256,1442,572,1038,3607,3407,1392,3168,2835&amp;a=4&amp;list=1&amp;itype=0&amp;hm=179"><input name="ottType" value="colstackedindexed" type="hidden"><input name="resultIds[product][0]" value="4108" type="hidden"><input name="resultIds[product][1]" value="2082" type="hidden"><input name="resultIds[product][2]" value="3514" type="hidden"><input name="resultIds[product][3]" value="2976" type="hidden"><input name="resultIds[product][4]" value="4163" type="hidden"><input name="resultIds[product][5]" value="3191" type="hidden"><input name="resultIds[product][6]" value="4365" type="hidden"><input name="resultIds[product][7]" value="1580" type="hidden"><input name="resultIds[product][8]" value="255" type="hidden"><input name="resultIds[product][9]" value="2778" type="hidden"><input name="resultIds[product][10]" value="3615" type="hidden"><input name="resultIds[product][11]" value="1887" type="hidden"><input name="resultIds[product][12]" value="4101" type="hidden"><input name="resultIds[product][13]" value="462" type="hidden"><input name="resultIds[product][14]" value="3509" type="hidden"><input name="resultIds[product][15]" value="4473" type="hidden"><input name="resultIds[product][16]" value="3060" type="hidden"><input name="resultIds[product][17]" value="1599" type="hidden"><input name="resultIds[product][18]" value="2399" type="hidden"><input name="resultIds[product][19]" value="205" type="hidden"><input name="resultIds[product][20]" value="2183" type="hidden"><input name="resultIds[product][21]" value="1159" type="hidden"><input name="resultIds[product][22]" value="2034" type="hidden"><input name="resultIds[product][23]" value="3256" type="hidden"><input name="resultIds[product][24]" value="1442" type="hidden"><input name="resultIds[product][25]" value="572" type="hidden"><input name="resultIds[product][26]" value="1038" type="hidden"><input name="resultIds[product][27]" value="3607" type="hidden"><input name="resultIds[product][28]" value="3407" type="hidden"><input name="resultIds[product][29]" value="1392" type="hidden"><input name="resultIds[product][30]" value="3168" type="hidden"><input name="resultIds[product][31]" value="2835" type="hidden"><input name="resultIds[area][0]" value="4" type="hidden"><input name="globalOptions[sortOrder][phase]" value="pD" type="hidden"><input name="globalOptions[sortOrder][inactive_date]" value="iA" type="hidden"><input name="globalOptions[sortOrder][start_date]" value="sA" type="hidden"><input name="globalOptions[sortOrder][overall_status]" value="oA" type="hidden"><input name="globalOptions[sortOrder][enrollment]" value="eA" type="hidden"><input name="globalOptions[type]" value="activeTrials" type="hidden"><input name="globalOptions[enroll]" value="0" type="hidden"><input name="globalOptions[itype][0]" value="0" type="hidden"><input name="globalOptions[version]" value="MA%3D%3D" type="hidden"><input name="globalOptions[page]" value="1" type="hidden"><input name="globalOptions[onlyUpdates]" value="no" type="hidden"><input name="globalOptions[encodeFormat]" value="old" type="hidden"><input name="globalOptions[LI]" value="1" type="hidden"><input name="globalOptions[minEnroll]" value="0" type="hidden"><input name="globalOptions[maxEnroll]" value="2200" type="hidden"><input name="globalOptions[startrange]" value="now" type="hidden"><input name="globalOptions[endrange]" value="1 month" type="hidden"><input name="globalOptions[sphinxSearch]" value="" type="hidden"><input name="globalOptions[includeProductsWNoData]" value="off" type="hidden"><input name="globalOptions[showTrialsSponsoredByProductOwner]" value="off" type="hidden"><input name="globalOptions[resetLink]" value=",list=1,itype=0,hm=179" type="hidden"><input name="globalOptions[Highlight_Range][0]" value="1 week" type="hidden"><input name="globalOptions[Highlight_Range][1]" value="2 weeks" type="hidden"><input name="globalOptions[Highlight_Range][2]" value="1 month" type="hidden"><input name="globalOptions[Highlight_Range][3]" value="1 quarter" type="hidden"><input name="globalOptions[Highlight_Range][4]" value="6 months" type="hidden"><input name="globalOptions[Highlight_Range][5]" value="1 year" type="hidden"><input name="globalOptions[url]" value="p=4108,2082,3514,2976,4163,3191,4365,1580,255,2778,3615,1887,4101,462,3509,4473,3060,1599,2399,205,2183,1159,2034,3256,1442,572,1038,3607,3407,1392,3168,2835&amp;a=4" type="hidden"><input name="globalOptions[hm]" value="179" type="hidden"><ul><li><label>Number of Studies: </label></li><li><select id="dOption" name="dOption" size="2" style="height: 54px;"><option value="shown" selected="selected">38 Shown Studies</option><option value="all">104 Found Studies</option></select></li><li><label>Which Format: </label></li><li><select id="wFormat" name="wFormat" size="3" style="height: 54px;"><option value="excel" selected="selected">Excel</option><option value="pdf">PDF</option><option value="tsv">TSV</option></select></li></ul><input name="shownCnt" value="38" type="hidden"><input id="btnDownload" name="btnDownload" value="Download File" style="margin-left: 8px;" type="submit"></form></div></div></div><script type="text/javascript">cssdropdown.startchrome("chromemenu");</script><br><br><div style="height: 50px;"></div><div id="slideout">
    <img src="help.png" alt="Help">
    <div class="slideout_inner">
        <table class="table-slide" bgcolor="#FFFFFF" cellpadding="0" cellspacing="0">
        <tbody><tr><td width="15%"><img src="black-diamond.png" alt="Data release"></td><td>Click for data release</td></tr>
        <tr><td><img src="red-diamond.png" alt="Data release (new)"></td><td>Click for data release (new)</td></tr>
        <tr><td><img src="hourglass.png" alt="Results pending"></td><td>Results pending</td></tr>
        <tr><td><img src="black-checkmark.png" alt="Milestone result"></td><td>Click for milestone result</td></tr>
        <tr><td><img src="red-checkmark.png" alt="Milestone result (new)"></td><td>Click for milestone result (new)</td></tr>
        <tr><td><img src="purple-bar.png" alt="Milestone details"></td><td>Click for milestone details</td></tr>
        <tr><td><img src="down.png" alt="Milestones"></td><td>Display milestones</td></tr>
        <tr><td colspan="2" style="padding-right: 1px;">
         <div style="float: left; padding-top: 3px;">Phase&nbsp;</div>
         <div class="gray">N/A</div>
         <div class="blue">0</div>
         <div class="green">1</div>
         <div class="yellow">2</div>
         <div class="orange">3</div>
         <div class="red">4</div>
         </td></tr>
        </tbody></table>
    </div>
</div>
<script type="text/javascript">
	$(function() 
	{
		$enrollValues = '0';
		if($enrollValues == '0')
		{	
			$minEnroll = parseInt($("#minenroll").val());
			$maxEnroll = parseInt($("#maxenroll").val());
		}
		else
		{
			$enrollValues = $enrollValues.split(' - ');
			$minEnroll = parseInt($enrollValues[0]);
			$maxEnroll = parseInt($enrollValues[1]);
		}
		
		$("#slider-range").slider({
			range: true,
			min: $("#minenroll").val(),
			max: (($("#maxenroll").val() > 5000) ? 5000 : $("#maxenroll").val() ),
			values: [ parseInt($minEnroll), parseInt($maxEnroll) ],
			slide: function( event, ui ) {
				if(ui.values[ 1 ] == 5000)
				{
					$("#amount").val(ui.values[ 0 ] + " - " + 5000 + "+" );
				}
				else
				{
					$("#amount").val(ui.values[ 0 ] + " - " + ui.values[ 1 ] );
				}
			}
		});
		
		if($("#slider-range").slider("values", 1) == 5000)
		{
			$("#amount").val( $("#slider-range").slider("values", 0 ) +
				" - " + 5000 + '+' );
		}
		else
		{
			$("#amount").val( $("#slider-range").slider("values", 0 ) +
				" - " + $("#slider-range").slider("values", 1 ));
		}
		
				//highlight changes slider
		$("#slider-range-min").slider({
			range: false,
			min: 0,
			max: 6,
			step: 1,
			values: [ 0, 3 ],
			slide: function(event, ui) {
				if(ui.values[0] > ui.values[1])	/// Switch highlight range when sliders cross each other
				{
					$("#startrange").val(timeEnum(ui.values[1]));
					$("#endrange").val(timeEnum(ui.values[0]));
				}
				else
				{
					$("#startrange").val(timeEnum(ui.values[0]));
					$("#endrange").val(timeEnum(ui.values[1]));
				}
			}
		});
				
		$("ul #productbox li").click(function () {
			var $checkbox = $(this).find(":checkbox");
			$checkbox.prop('checked', !$checkbox.attr('checked'));

		});
		
		$('#productbox li input, #productbox li label').click(function(event){
			event.stopPropagation();
		});
		
		$('body').keydown(function(e)
		{	
			if (e.keyCode == 13) 
			{
			  $('#frmOtt').submit();
			} 
		});
		
		$(window).load(function(){
			$("#outercontainer").mCustomScrollbar({
				horizontalScroll:true,
				scrollButtons:{
					enable:false,
					scrollType:"pixels",
					scrollAmount:116
				}
			});
		});
		
		$("#togglefilters").toggle( function() {
		   $('.controls').css({ 'display' : ''});
		}, function () {
		   $('.controls').css({ 'display' : 'none'});
		});
		
		divresize();
	});

	function timeEnum($timerange)
	{
		switch($timerange)
		{
			case 0: $timerange = "now"; break;
			case 1: $timerange = "1 week"; break;
			case 2: $timerange = "2 weeks"; break;
			case 3: $timerange = "1 month"; break;
			case 4: $timerange = "1 quarter"; break;
			case 5: $timerange = "6 months"; break;
			case 6: $timerange = "1 year"; break;
		}
		return $timerange;
	}
	
	function timeEnumforGuests($timerange)
	{
		switch($timerange)
		{
			case 0: $timerange = "now"; break;
			case 1: $timerange = "1 week"; break;
			case 2: $timerange = "2 weeks"; break;
			case 3: $timerange = "1 month"; break;
			case 4: $timerange = "1 quarter"; break;
			case 5: $timerange = "6 months"; break;
			case 6: $timerange = "1 year"; break;
		}
		return $timerange;
	}
	
	function divresize() 
	{  
		/*var windoWidth;
		var documentWidth = $(document).width();
		var manageWidth = $('.manage').width();
		var controlsWidth = $('.controls').width();
		windoWidth = (documentWidth > manageWidth && documentWidth > controlsWidth ? documentWidth : manageWidth > controlsWidth ? manageWidth : controlsWidth);
		$('#parent').width(windoWidth);
		$('.manage').width(windoWidth);*/
		
		var windowidth = $('.manage').width();
		$('#parent').width(windowidth);
		
		var filterwidth = $('#togglefilters').width();
		var recordswidth = $('.records').width();
		var searchboxwidth = $('#fulltextsearchbox').width();
		var paginationwidth = $('.pagination').width();
		var buttonswidth = $('#buttons').width();
		var milestoneswidth = $('.milestones').width();
		var exportwidth = $('.export').width();
		
		var ocontrolswidth = (filterwidth+recordswidth+searchboxwidth+paginationwidth+buttonswidth+milestoneswidth+exportwidth+110);
		$('#outercontainer').width(windowidth - ocontrolswidth);
 	} 
	
	$(window).resize(function() {
		divresize();
	}); 
</script>

</body>
</html>
